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1 SUMMARY 
 
C1q-deficiency is strongly associated with the development of systemic lupus 
erythematosus (SLE) in humans and lupus-like autoimmunity in mice. Often, macrophages 
(MPs) show a reduced ability to engulf apoptotic cells in SLE patients. In agreement with this, 
it has been shown that C1q-KO mice show impaired engulfment of dead cells. However, the 
precise mechanisms how this leads to the development of SLE is unclear. Using apoptotic 
cells with fluorescently-labeled H2B histones, we could show that C1q-KO peritoneal 
macrophages (pMPs) exhibit a delayed degradation of nuclear material derived from 
phagocytosed apoptotic cells. We found a significant reduction of lysosomal DNASE2A in  
C1q-KO splenic enriched MPs and pMPs which is necessary for digesting the engulfed 
apoptotic nuclear material. As a consequence, C1q-KO MPs show elevated levels of factors 
involved in the STING-pathway, which is activated by recognition of cytosolic DNA. We also 
found significant reduction of RAB5 in C1q-KO MPs which is necessary for maintaining the 
endo-lysosomal system. In addition, enlarged lysosomal compartments were seen in C1q-KO 
MPs which is an indication of dysfunctional lysosomes. In order to restore the degradation of 
phagocytosed nuclear material, we coated apoptotic cells with a DNASE2A fused to the 
apoptotic-cell binding protein MFGE8, to deliver DNASE2A directly to the lysosomes 
containing DNA of phagocytosed apoptotic cells. This not only restored DNA-degradation in 
C1q-KO MPs, but also lead to reduced production of inflammatory cytokines upon 
phagocytosis. Hence, we postulate that C1q-deficiency leads to accumulation of non-degraded 
DNA in phagocytic cells triggering production of pro-inflammatory cytokines via the STING 
pathway. In addition, reduced DNASE2A expression could be a consequence of the disrupted 
endo-lysosomal system seen in C1q-KO MPs. 
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2 ZUSAMMENFASSUNG 
 
Der C1q-Mangel ist stark mit der Entwicklung des systemischen Lupus erythematodes 
(SLE) beim Menschen und der lupusartigen Autoimmunität bei Mäusen verbunden. Häufig 
zeigen Makrophagen eine verminderte Fähigkeit, apoptotische Zellen bei SLE-Patienten zu 
aktivieren. In Übereinstimmung damit wurde gezeigt, dass C1q-defiziente Mäuse eine 
beeinträchtigte Phagozytose toter Zellen aufweisen. Die genauen Mechanismen, wie dies zur 
Entwicklung von SLE führt, sind jedoch unklar. Wir fanden eine signifikante Reduktion von 
lysosomaler DNase2a bei C1q-defizienten Milz- und Peritonealmakrophagen, die für den 
Abbau des phagozytierten apoptotischen Kernmaterials notwendig ist. Unter Verwendung von 
apoptotischen Zellen mit fluoreszenzmarkierten H2B-Histonen konnten wir zeigen, dass      
C1q-defiziente peritoneale Makrophagen einen verzögerten Abbau von Kernmaterial aus 
phagozytosierten apoptotischen Zellen aufweisen. Infolgedessen zeigen C1q-defiziente 
Makrophagen erhöhte Werte von Faktoren, die am STING-Signalleitungsweg beteiligt sind, 
der durch die Erkennung zytosolischer DNA aktiviert wird. Wir fanden auch eine signifikante 
Reduktion von RAB5 in C1q-defizienten Makrophagen, die für die Aufrechterhaltung des endo-
lysosomalen Systems notwendig ist. Darüber hinaus wurden vergrößerte lysosomale 
Kompartimente in C1q-KO-Makrophagen beobachtet, was ein Hinweis auf dysfunktionale 
Lysosomen ist. Um den Abbau von phagozytosiertem Kernmaterial wiederherzustellen, haben 
wir apoptotische Zellen mit DNASE2A beschichtet, die mit dem apoptotischen 
Zellbindungsprotein MFGE8 fusioniert ist, um DNASE2A direkt an die Lysosomen zu liefern, 
die DNA von phagozytosierten apoptotischen Zellen enthalten. Dadurch wurde nicht nur der 
DNA-Abbau in C1q-defizienten Makrophagen wiederhergestellt, sondern auch die Produktion 
von inflammatorischen Zytokinen bei Phagozytose reduziert. Daher postulieren wir, dass C1q-
Mangel zu einer Anhäufung von nicht abgebauter DNA in phagozytischen Zellen führt, die die 
Produktion von proinflammatorischen Zytokinen über den STING-Weg auslöst. Darüber 
hinaus könnte eine reduzierte DNASE2A-Expression eine Folge des gestörten endo-
lysosomalen Systems sein, das in C1q-defizienten Makrophagen beobachtet wird. 
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3 INTRODUCTION 
3.1 The immune system 
Multicellular organisms have evolved their own defense strategies to fight off 
pathogens. The body is protected from various infectious and harmful agents by a variety of 
effector cells and molecules that together make up the immune system. The collective and 
coordinated signals from the immune system to pathogens (eg., protozoans, virus and 
bacteria) are termed immune response. The immune system is broadly classified as innate 
and adaptive immunity. Innate immunity comprises physical barriers (skin and mucosal), 
chemical barriers (anti-microbial peptides), blood proteins (complement) and cellular 
components (macrophages (MPs), neutrophils and NK cells). Innate immunity serves as the 
first line of defense and relies on a limited number of receptors and secreted proteins that 
recognize a wide variety of pathogens. Early responses to pathogens are mediated by innate 
immunity followed by a very specific immune responses termed adaptive immunity. 
When an infection overwhelms innate immune defense mechanisms, an adaptive 
immune response is initiated. Nevertheless, the adaptive immune system with its large range 
of repertoire of antigen-specific receptors produced by somatic recombination is able to 
recognize virtually any microbial and non-microbial antigen. The high affinity receptors of B 
cells and T cells are accomplished through a process called V(D)J-recombination which allows 
the generation of a very large number of different specificities from a limited number of genetic 
segments. B cells and T cells with high affinity receptors are the cellular components that exert 
their immune responses towards pathogens. Some specialized antigen presenting cells 
(APCs) act as a bridge between innate and adaptive immune system in order to activate T and 
B cells thereby initiating the adaptive immune responses. Adaptive immunity is further 
subdivided into humoral immunity and cell-mediated immunity. Humoral immunity is mediated 
by antibodies produced by B cells. Successful elimination of extracellular microbes and toxins 
is facilitated by binding of secreted antibodies to the pathogen surface. On the other hand, cell-
mediated immunity is effective against intracellular pathogens proliferating inside the MPs or 
other host cells. 
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The failure or breakdown of mechanisms maintaining self-tolerance in B and T cell 
results in autoimmunity. Loss of self-tolerance results in abnormal selection of self-reactive 
lymphocytes thereby presenting self-antigens to the immune system [1]. MPs contribute to 
autoimmunity and inflammation through their ability to present autoantigens and through its 
potent effector mechanisms during innate and adaptive immunity. 
 
3.2 Mononuclear Phagocyte System 
The mononuclear phagocyte system (MPS) was established by van Furth [2] that 
consists of myeloid immune cells such as monocytes, MPs but not granulocytes though 
dendritic cells were included following their discovery. The homeostasis of tissue resident MPs 
relies on the constant recruitment of blood monocytes developed from committed bone marrow 
precursors [3]. Tissue resident MPs are heterogenous immune cells which fulfill tissue-specific 
and niche-specific functions. Tissue resident MPs have dedicated homeostatic functions such 
as apoptotic cell clearance, response to infection and the resolution of inflammation [4]. In the 
beginning, it was considered that both monocytes and MPs are related cell types arising from 
a continuous differentiation. Nevertheless, these initial concepts were later challenged with 
fate mapping studies to identify their respective origin. At present it is established that classical 
MPs and DCs reside in tissues whereas monocytes reach the inflammation site from blood 
circulation only on demand. The origin and characteristics of each cell types are discussed 
further in detail. 
3.2.1 MPs 
MPs are specialized immune cells of innate immune system involved in the 
phagocytosis and neutralization of potential pathogens. The MP functions are mainly restricted 
to their immediate surroundings in which they differ from mobile DCs specialized in triggering 
remote T cell responses upon their translocation to tissue-draining lymph nodes [5]. MPs are 
functionally grouped into two classes, known as “M1-M2” paradigm [6]. M1 MPs are classically 
activated MPs associated with inflammatory responses while the tissue resident MPs are 
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categorized as “M2-like” with their functions contributing towards the maintenance of tissue 
homeostasis and resolution of inflammation [4], [6].  
 
Figure 3.1: Tissue resident MPs have a wide range of function in clearance, development and metabolic regulation. 
This figure is adapted from [4]. 
 
Tissue MPs play an important role in immunosurveillance in their close surroundings. 
This patrolling function of MPs is achieved with the help of wide array of danger sensing 
molecules like scavenging receptors, pattern recognition receptors (TLRs, C-type lectins 
receptors, RIG-1 and NOD), cytokine receptors and adhesion molecules. Once  pathogens are 
sensed by MPs they eliminate them with the help of a highly developed lysosomal 
compartment abundant in critical protease and bactericidal activity [7]. However, the wide array 
of receptor and effector functions of MPs are dependent on their local adaptation to different 
tissues [8]. The wide range of tissue resident MPs and their functions are shown in Figure 3.1 
3.2.1.1 Development and heterogeneity of tissue MPs in vivo 
The majority of adult tissue MPs is seeded prenatally from embryonic progenitors and 
can maintain themselves by self-renewal. Primitive MPs appear at first within the yolk sac blood 
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islands. These MPs follow a ‘fast-track’ differentiation pathway without a monocytic 
intermediate to become mature fetal tissue MPs completely dependent on transcription factor 
PU.1 [9], [10]. Once the circulatory system is fully established, yolk-sac derived MPs migrate 
into the embryonic tissues via circulation and develop into a fetal MP population [11]. However, 
it is unclear if yolk-sac derived MPs persist into adulthood and if they act as a sole source of 
adult tissue specific MPs. Following the appearance of yolk-sac derived MPs, monocytes 
differentiate in the fetal liver from pro-monocytic intermediates and resemble adult monocytes 
as they express CD11b, F4/80, Ly6C and CSFIR [12], [13]. CD11b mediates inflammation, 
chemotaxis, phagocytosis and is also involved in the complement system by binding iC3b. 
F4/80 is a member of adhesion G-protein coupled receptor (GPCR) family widely expressed 
in mouse MPs and some circulating monocytes. Ly6C is expressed on MP and DC-precursors, 
granulocytes and wide range of endothelial cells, B and T cell subpopulations. These 
monocytes are released into circulation and later recruited to fetal tissues. Once they reach 
embryonic fetal tissues, these monocytes proliferate and differentiate locally into MPs thus 
superseding the existing yolk-sac derived MPs as seen in alveolar MPs from lungs and heart 
MPs [14], [15]. Thus, tissue resident MPs derived either from embryonic or adult monocytic 
origin are exposed to many tissue-specific factors which influences their further development, 
function, and polarization. The specific functions and phenotype of splenic MPs and pMPs are 
discussed further in detail as they are extensively used in this current study. 
3.2.1.2 pMPs 
pMPs are one of the best characterized MP population and contributed much to our 
understanding of MP biology. These MPs are easily accessible and were used to study 
phagocytosis and signaling cascades [16], [17]. However, the specific functions and ontogeny 
of pMPs are still largely unknown. There are two different pMPs subsets which differ in 
phenotype and function. One minor subset represents F4/80intCD11bint pMPs which act as an 
on-demand precursor for F4/80hiCD11bhi pMP population. The F4/80hiCD11bhi pMP 
population dominates under steady-state conditions and is long-lived with limited self-renewal 
potential [18]. During inflammatory conditions, Ly6Chi monocytes infiltrate the peritoneum and 
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differentiate into a F4/80intCD11bint and subsequently into a F4/80hiCD11bhi population thereby 
integrating into the pMP network [19]. 
3.2.1.3 Splenic MPs  
Spleen is the largest lymphoid organ and a major site for initiation of T and B cell 
responses against blood-borne antigens. The various MP sub-populations are 
compartmentalized into specific splenic zones and perform their respective roles to maintain 
homeostasis [20]. The splenic microarchitecture consists of the white and red pulp separated 
by an interface termed marginal zone (MZ). The red pulp is involved in erythrophagocytosis as 
it is well equipped with a unique and efficient venous system [21]. The marginal zone is a 
region rich in B cells and several types of MPs. This zone contains two different MP sub-
populations defined as marginal zone macrophages (MZMs) and marginal metallophilic 
macrophages (MMMs). MZMs are localized in the outer layer of marginal zone and express 
CD204, MARCO and SIGN-R1 as pattern recognition receptors. These cells play a major role 
in the capture of blood borne antigens [22]–[24]. MZMs also interact with MZ B cells which play 
an important role in attracting and retaining MZMs by chemokine secretion (CCL19 and CCL2) 
[25]. MMMs or MZMs located in the inner layer of marginal zone are identified by CD169 
expression which mediates the uptake of sialic acid expressing bacteria [26]. On the other 
hand, CD169+ MPs also trap viruses and immune complex and present them in an intact form 
to follicular B cells and induce GC B cell responses [27]. In addition, CD169+ MPs are important 
to initiate T cell responses [28]. When antigens are specifically targeted to CD169+ MPs,  
BATF-3 dependent cross-presentation to CD8+ DCs is required for cross-priming of CD8+                
T cells [29]. 
  8 
 
Figure 3.2 Organization of different cell types in mouse spleen. This figure is adapted from [4]. 
 
Follicular dendritic cells (FDCs) are located in the primary B cell follicles and germinal 
centers (GCs) of spleen. FDCs retain immune complexed antigen in B cell follicles to facilitate 
the GC-reaction [30]. The white pulp MPs are identified by CD68 and include tingible body 
macrophages (TBMs). These TBMs are located in germinal centers and play crucial role in 
phagocytosis of apoptotic GC B cells during a germinal center reaction. Milk-Fat Globule 
Epidermal growth factor 8 (MFGE8) and receptor tyrosine kinase MerTK play important roles 
in clearance of apoptotic cells by TBMs. FDCs provide TBMs with MFGE8 thereby favoring the 
disposal of apoptotic B cells [31], [32]. The major cell components in splenic microarchitecture 
is depicted in Figure 3.2. The functions of MFGE8 are discussed more in detail under section 
3.4.2.1. 
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3.3 Cell death pathways 
During the developmental or inflammatory processes and from mechanical stress 
billions of cells die as an everyday routine in a programmed fashion and is hence termed 
programmed cell death [33]. Based on the biochemical and morphological characteristics, cell-
death processes are classified into three major categories as follows: Apoptosis, necrosis and 
NETosis [34]. Some of the other forms of programmed cell death identified are ferroptosis, 
necroptosis and pyroptosis. Any one of the above process could cause the modification of self-
antigens coupled with its inefficient clearance, acting as a driving force for tolerance break, 
further augmented by generation of an inflammatory milieu [35]. 
3.3.1 Apoptosis 
Apoptosis is considered to be immunologically silent. It is required to maintain 
homeostasis by efficient replacement of many dying cells with healthy cells which occur during 
development, aging and immune responses for example. This mode of cell death is 
accompanied by a change in morphological features such as cell shrinkage, chromatin 
condensation, cytoskeletal remodeling, nuclear fragmentation and plasma membrane blebbing 
[36]. During apoptosis, the membrane integrity is maintained avoiding leakage of intracellular 
auto-antigens and hence triggering of immune responses by such antigens is prevented [37]. 
Effector caspases are proteolytically activated from apoptosis which could be initiated either 
extrinsically (death-receptor mediated) by caspase-8 or intrinsically (mitochondrial) by 
caspase-9 [38]. The high amount of protein cleavage during apoptosis is probably responsible 
for morphological and biochemical changes which lead to subsequent killing of cells.  
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Figure 3.3: Apoptosis pathways are initiated either in an intrinsic or extrinsic manner. Figure is adapted from [39]. 
 
Intrinsic pathways are activated by intrinsic lethal signals such as DNA damage, 
hypoxia and metabolic stress. These signals further activate BCL-2 family members (BH3 - 
members) which are transcriptionally up-regulated and further stimulate the release of 
cytochrome C from mitochondria whereas anti-apoptotic members inhibit the release of 
cytochrome C. The released cytochrome C functions together with APAF-1 and activated 
caspase 9 which leads to the activation of downstream caspases (caspase 3 and caspase 7). 
The extrinsic death pathway is activated by Fas ligand (FasL), Tumor necrosis factor (TNF) 
and TNF-related apoptosis-inducing ligand (TRAIL). The binding of FasL to its Fas receptor 
leads to the formation of death inducing signal complex (DISC). The major components of 
DISC are Fas, adaptor proteins and procaspase-8. The activation pathways downstream of 
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caspase 8 is different in each cell type. Caspase 8 directly activates caspase 3 to kill dying 
thymocytes. On the other hand, caspase 8 cleaves Bid and then cleaved Bid (tBid) stimulates 
cytochrome C release and further leads to activation of caspase 9 - caspase 3 pathway in 
hepatocytes [40]–[42]. The sequential steps for intrinsic and extrinsic cell death pathways are 
shown in Figure 3.3. 
3.3.2 Necrosis 
Necrosis was once considered to be an uncontrolled mode of cell death that happens 
due to severe membrane damage. This results in a rapid redistribution of cellular constituents 
followed by massive cell swelling and cell rupture liberating intracellular danger signals called 
danger associated molecular pattern (DAMPs). DAMPs act as endogenous danger signals to 
promote inflammation. Some of the most common DAMPs are high mobility group box-1 
(HMGB1), calgranulin A, calgranulin B and serum amyloid A (SAA). However, from recent 
studies it is evident that necrosis is also a process that occurs in a tightly regulated manner 
completely unrelated to cell injury [43], [44]. This programmed form of necrosis is known 
necroptosis or inflammatory cell death. Necroptosis represents an alternative cell death mode 
that is a consequence of RIPK3 activation due to the presence of TNF, Fas, TRIAL, TLR 
stimulation and some caspase inhibitors [45]–[50]. Necroptosis seems to be highly dependent 
on RIPK3 and MLKL, however not all cell tissues express RIPK3. As a consequence, not all 
cells are able to follow a necrotic cell death pathway [49], [51]. 
3.3.3 NETosis 
Neutrophils are one of the major cellular components of first line defense mechanism 
against invading pathogens. These cells migrate to the site of inflammation, and their defense 
mechanisms include phagocytosis of pathogens, degranulation, cytokine production and 
neutrophil extracellular trap (NET) formation [52], [53]. NETs are made up of fibrous network 
assembly from nuclear and granular components which protrudes from activated neutrophils 
[54]. The special structure of NETs helps to trap the pathogens followed by killing with 
respiratory bursts followed by cell death [55]. NETosis is a process of active NET formation 
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and subsequent release of NETs. The release of mitochondrial ROS mediated by NADPH 
oxidase activation is an important requirement for an effective NETosis. Inflammasomes are 
activated by NETs and favor subsequent synthesis of IL-1 and IL-18 which in turn further 
induces NET formation [56]. IL-8 is known to adhere locally to activated endothelial cells and 
generates NETs positive for Proteinase-3 and Myeloperoxidase [57], [58]. NETs are a potent 
source of autoantigens and their impaired clearance has been reported in many cases of SLE 
[59].  
 
3.4 Phagocytosis  
Cell death pathways release many particles which are efficiently taken up by 
phagocytes to maintain homeostasis. The cellular uptake of particles (<0.5 m) within a plasma 
membrane envelope is termed phagocytosis. The maintenance of homeostasis by the removal 
of dead cells depends much on the presence and nature of phagocytes [60]. The uptake 
mechanisms differ depending on the particle size and receptor-ligand interactions. Following 
the engulfment, early phagosome vacuoles fuse with primary lysosomes or with products from 
the endoplasmic reticulum (ER) and Golgi complex which results in formation of a secondary 
phagolysosome. The entire process is highly dynamic and tightly regulated which involves 
fusion and fission events with endocytic and secretory vesicles resulting in acidification. This 
aids in cargo digestion and is accompanied by membrane recycling [61]. The phagocytic 
particles can be generated from apoptosis, necrosis or microbial infection. It is a specific task 
for the phagocytes to distinguish between live or senescent cells, pathogens from commensals 
and infected from uninfected cells [62].  
The phagocytes which take up apoptotic cells are classified as “professional”, “non-
professional” and “specialized” phagocytes. Apoptotic cells generated in vivo are recognized 
by professional phagocytes and subsequently engulfed to prevent the release of intracellular 
material which could be immunogenic at some point. MPs and immature DCs are categorized 
as professional phagocytes which show higher capabilities with respect to apoptotic cell 
engulfment both in vitro and in vivo [63]. Tissue resident MPs such as pMPs, Kupffer cells in 
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the liver, microglia in the brain and alveolar MPs in the lungs are also classified as professional 
phagocytes [3]. Apart from this, circulating monocytes are recruited at the time of inflammation 
and tissue injury. These recruited phagocytes may either compete or co-operate with tissue 
resident MPs in taking up dead cells [64]. Epithelial cells and fibroblasts are categorized as 
“non-professional” phagocytes as they engulf dead cells with lower efficiencies during a MP 
deficient situation as in PU.1 deficient mouse embryos [65]. Specialized phagocytes are multi-
functional phagocytes such as Sertoli cells in testes and retinal pigment epithelial cells (RPE) 
which exert their function only in specific tissue-contexts [66], [67].  
3.4.1 Communication between phagocytes and apoptotic cells 
The major source of  particles for phagocytosis can be either apoptotic and necrotic 
cells or microbial material [62]. The engulfment of apoptotic material by phagocytes depends 
on a number of early steps. For an effective dead cell clearance, positioning of professional 
phagocytes close to apoptotic cells is important. This is achieved by maintaining phagocyte 
migration and apoptotic cell motility [68]. Phagocytes face the challenge to find dying cells 
among healthy cells. This is facilitated with the release of certain molecules from dying cells 
termed “find me signals” which recruit or activate phagocytes. The attracted phagocytes 
through their engulfment receptors sense  “eat me signals” produced by dying cells [69].  
Such “find me signals” are Sphingosine-1-Phosphate (S1P) and CX3CL1/fractalkine. 
SIP binds to its SIP-1R receptor on MPs and promotes chemotaxis of MPs. SIP1 is generated 
by Sphingosine kinase and secreted by apoptotic cells in a caspase dependent manner. 
CX3CR1 released from apoptotic cells activates MPs by its subsequent binding to its receptor 
CX3CR [70], [71]. The role of ATP and UTP produced by apoptotic cells to serve as “find me 
signals” is yet to be clearly established [72]. 
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Figure 3.4: Apoptotic cell recognition by phagocytes. A number of membrane receptors on the phagocytes are involved in 
sensing the molecules produced by apoptotic cells. Figure is adapted from [73]. 
 
Phosphatidylserine (PS) is a plasma membrane component which remains exclusively 
on the inner side of the lipid bilayer in healthy cells [74]. PS is exposed on the outer side of the 
lipid bilayer when a cell undergoes apoptosis [75]. PS is mostly externalized in a caspase 3-
mediated cleavage of scramblase Xkr8 [76]. The inhibition of apoptotic cell engulfment has 
been observed when PS is masked in both in vitro and in vivo studies [77], [78]. Thus, PS is 
one of the best described “eat me signal”. In addition to PS some of the moieties expressed 
on apoptotic cells include calreticulin, complement C1q, annexin I and a modified form of 
intracellular adhesion molecule-3 (ICAM-3) [73]. On the other hand, CD47 has been proposed 
as “don’t eat me signal ” following the observation that CD47- red blood cells are cleared more 
rapidly by splenic MPs compared to CD47+ apoptotic cells [79]. The wide range of membrane 
receptors involved in sensing apoptotic cells are shown in Figure 3.4. Following the successful 
recognition of an apoptotic cell by phagocytes, an extensive cytoskeletal rearrangement occurs 
to internalize corpses thereby processing the ingested cargo. The uptake of apoptotic cells is 
followed by secretion of “tolerate me signal ” such as Transforming Growth Factor  (TGF-) 
and Interleukin-10 (IL-10) which further inhibits the recruitment of other MPs to the site of 
ongoing cell death and stops the secretion of pro-inflammatory cytokines such as TNF-, IL-1 
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and IL-12 [80]. This elicits anti-inflammatory responses which dampen the local immune 
responses at the sites were apoptotic cell death occurs [63].  
3.4.2 Scavenging receptors 
Phagocytosis can occur either via opsonic or non-opsonic dependent mechanisms. 
Opsonic dependent phagocytosis is dependent on the molecules called opsonin that bind to 
the cell surface thereby enhancing phagocytosis by other phagocytes. Opsonic phagocytosis 
is dependent either on the binding of IgG antibodies or complement proteins to be taken up 
either via Fc or complement receptors respectively. Some of the notable opsonic receptors are 
FcR (activating or inhibitory) and complement receptor CR3. Fc receptors (FcR) bind 
conserved domains of IgG antibodies. CR3 is responsible for recognizing iC3b deposited by 
classical IgM or IgG or alternate lectin pathways of complement activation [81]. Other cell 
derived opsonin includes fibronectin, mannose-binding lectin, MFGE8 and other phagocyte 
receptor ligands [82]. Non-opsonic phagocytosis is dependent mostly on pattern recognition 
receptors (PRRs). Non-opsonic receptors include CD169 and CD33 recognizing sialylated 
residues [83]. Dectin-1 recognizes fungal beta-glucan [60], [84] and other related C-type lectins 
such as Dectin-2, MICL, Mincle and DNGR-1 recognizes many fungal related structures [85], 
[86]. Though TLRs are considered as good sensors, they always function together with other 
non-opsonic receptors to aid efficient uptake and signaling [62]. 
3.4.2.1 Milk-fat globule epidermal growth factor 8 (MFGE8)  
MFGE8, also known as lactadherin, has been found associated with milk fat globules 
in mammary glands which is a secreted protein present on many phagocytes involved in 
apoptotic cell engulfment [87]. MFGE8 is predominantly expressed mostly by MPs, immature 
DCs, mammary epithelial and retinal pigment epithelial cells [31], [88], [89]. MFGE8 acts as a 
link between MPs and their target apoptotic cells thereby establishing its role as opsonin [82]. 
Murine MFGE8 comprises two repetitive mouse epidermal growth factor (EGF) 
domains on the N-terminus carrying a highly conservative RGD (Arg, Gly, Asp) motif in the     
B-loop of EGF domain. It carries two factors-VII-homologous domains (C1 and C2) in its                
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C-terminal region together with Proline-Threonine (PT)-rich domain. MFGE8 is bound by v3 
or v5 integrins on phagocytes through its RGD motif [90]. It binds tightly to PS through its C2 
domain thereby further promotes the apoptotic cell engulfment [91].  
MFGE8-/- mice develop an age-dependent SLE type of autoimmune diseases. This is 
also characterized with increased levels of anti-double stranded DNA (dsDNA), anti-nuclear 
antibodies (ANA), immune complex deposits in glomeruli of kidneys and proteinuria. Tingible 
body macrophages (TBMs) from MFGE8-/- mice show an impaired removal of apoptotic cells 
from germinal centers. Without MFGE8, many apoptotic cells are left unengulfed by TBMs in 
the germinal center. These unengulfed cells undergo secondary necrosis and release cellular 
components thereby providing a trigger to activate immune system resulting in the generation 
of autoantibodies. The onset of disease in MFGE8-/- mice aggravate upon immunization as this 
induces germinal centers and thereby increases the load of apoptotic cells [88], [92]. 
3.4.2.2 Additional PS receptors 
Furthermore, there are other receptors such as TIM-1, TIM-4, BAI1 and MerTK which 
also have the ability to recognize PS on apoptotic cells. These receptors play their role in the 
absence of MFGE8 in cells such as pMPs [93]–[95]. First, TIM-1 and TIM-4 are composed of 
an immunoglobulin V (IgV) domain, a mucin-like domain, a transmembrane domain, a 
cytoplasmic region and a signal sequence. The bridging between TIM-1/TIM-4 and PS occurs 
via their respective IgV domain [93]. TIM-4 acts only as a tethering receptor but does not 
activate the downstream signaling pathways [96]. TIM-4 is highly expressed on tissue resident 
MPs, dendritic cells and pMPs [97]. TIM-3 has also been shown to bind PS and facilitate 
apoptotic cell engulfment however, less efficiently compared to TIM-1/TIM-4 [98]. Secondly, 
brain specific angiogenesis inhibitor (BAI1), is capable for PS engagement and initiates 
intracellular signaling to mediate apoptotic cell engulfment. Once BAI1 recognizes PS, BAI1 
interacts with a cytoplasmic module consisting of ELMO1 and DOCK180 which further induces 
actin cytoskeletal rearrangements facilitating the apoptotic cell uptake [94]. Lastly, Mer tyrosine 
kinase (MerTK) belongs to Tumor associated macrophages (TAM) receptor family. TAM 
receptors engage PS on apoptotic cells indirectly via other soluble bridging molecules such as 
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Protein-S and GAS-6 [95]. 
3.4.3 Apoptotic cargo processing 
Phagocytes recognize apoptotic material via appropriate cell-surface receptors 
followed by engulfment, by surrounding the dying cells with pseudopod-like structures. These 
pseudopods then fuse leading to the formation of an apoptotic cell containing membrane 
vacuole termed phagosome [99]. The nature of phagosomes is similar to an extracellular 
environment which has no degradation capacity. This nascent phagosome further undergoes 
phagosomal maturation leading to degradation of the ingested phagosomal contents. 
Phagosomal maturation involves a sequential fusion with early endosomes, late endosomes 
and eventually lysosomes [100]. During this process, nascent phagosomes acquire the 
properties from donor organelles such as specific markers as well as gradual acidification of 
phagosomal lumen [99]. Following this fusion, an intracellular hybrid compartment called 
phagolysosomes is formed which contains various digestive enzymes such as hydrolases, 
proteases, lipases, and glycosides. These digestive enzymes exhibit their optimal activities in 
an acidic environment of pH < 5.0 to effectively degrade the luminal contents [101]. 
 A continuous alteration of phagosome-associated molecules is required for the 
interaction with distinct endocytic organelles and thus leads to a successful phagosomal 
maturation [102]. The small Rab GTPases and lipid second messenger phosphatidylinositol 3-
phosphate are known for their critical role in phagosomal maturation. Rab GTPases regulate 
the membrane trafficking events by delivering apoptotic cargo to the appropriate subcellular 
destination [103]. Rab proteins associate themselves with the phagosome at different 
maturation states and facilitate the docking and fusion of intracellular organelles to 
phagosomes (Figure 3.5). Among the identified Rab GTPases; RAB-5, RAB-2, RAB-14 and 
RAB-7 are recruited sequentially to phagosomes undergoing the maturation process in              
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C. elegans [104]–[107]. 
RAB-5 through its conserved tethering activity, aids the 
anchoring of early endosomes to phagosomes containing 
apoptotic cells irrespective of phagocytic cargo identity [108].  
RAB-2 and RAB-7 play an important role in the recruitment and 
fusion of lysosomes to phagosomes. In addition, RAB-2 also plays 
an important role in the acidification of phagosomal lumen [104], 
[107]. The acidification of lysosomes is also aided by the activity of 
vacuolar type proton transporting ATPase (V-ATPase) which gains 
energy from ATP hydrolysis to pump protons from the cytosolic 
space to the phagosomal lumen [109]. Thus, an acidic environment 
acts as a favorable condition for an effective degradation of 
phagocytic content. 
3.4.4 Implications of impaired phagocytosis 
Professional and non-professional phagocytes engulf apoptotic cells in an 
immunologically silent manner. This is essential in a number of physiological process such as 
development and normal tissue homeostasis and in the resolution of inflammation [110]. When 
clearance of apoptotic cells is impaired, release of autoantigens such as double-stranded DNA 
(dsDNA) and the Sm antigens of the U1 small nuclear ribonucleoprotein complex can be the 
consequence. This can then result in the development of autoantibodies and autoimmunity 
[80], [111]. The inefficient clearance of apoptotic remnants could be an intrinsic defect and 
responsible for initiation of systemic autoimmunity in diseases such as Systemic Lupus 
Erythematosus (SLE) which is discussed in detail below. 
 
 
3.5 SLE - an autoimmune disorder 
SLE is a multi-system autoimmune disorder with defective clearance of apoptotic cells 
 
Figure 3.5: Role of RAB 
GTPases in sequential steps of 
phagosomal maturation. Figure 
is adapted and modified from 
[99]. 
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and which is assumed to be involved in the development of autoimmunity. SLE is characterized 
by impaired immune tolerance resulting in production of pathogenic auto-antibodies and 
immune complexes [112], [113]. These immune complexes are deposited in various organs 
which in turn cause inflammation and tissue damage. The most common disease 
manifestations include fever, facial rashes (“butterfly pattern”), arthritis, serositis, 
glomerulonephritis, thrombocytopenia, proteinuria, photosensitivity and, psychosis [114]. 
3.5.1 Epidemiology 
There is great variation in the extent of SLE pathogenesis across countries and different 
ethnic groups. Early disease phases may differ across ethnic groups which depends on their 
genetic makeup whereas at later stages it depends on their socio-economic status and access 
to medical treatment [115]. Populations of non-European ancestry are more affected as 
Europeans. Asian Americans, African Americans and Hispanic Americans are more 
susceptible and exhibit more complex manifestations than Caucasians [116]–[118]. Aboriginal 
Australians are more susceptible than non-Aboriginal Australians [119], [120]. About 65% of 
patients are in the age group of 16-55 years and 20% are diagnosed before the age of 16. The 
onset of Juvenile Systemic Lupus Erythematosus (JSLE) is mostly in the range of 14-20 years 
rarely before the age of 5 years [121], [122]. SLE is more prevalent in women compared to 
men which is attributed to immune-activating effects of estrogen via signaling by estrogen 
receptor  However, a clear correlation between female hormone concentrations and disease 
activity has not been established in human patients due to the complexity of other contributing 
genetic and environmental factors [123]. 
 
 
3.5.2 Etiological factors for SLE 
SLE is a very complex disease and it is impossible to narrow it down to a single factor 
responsible for triggering the disease. Genome-wide association studies (GWAS) are based 
on screening millions of genetic variants distributed throughout the whole-genome with respect 
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to a phenotype. There are about 60 risk loci identified from various GWAS studies many of 
which are associated with important signaling pathways (Fig. 3.6). 
 
  
Figure 3.6: Gene risk loci 
associated with SLE 
obtained using GWAS 
approach in European 
population. The immune 
functions of the identified 
genes could either fall 
under innate or adaptive 
immune pathways. This is 
the consolidated version of 
data presented in [124]. 
 
 
Epigenetic modifications such as reduced DNA methylation, histone hypoacetylation 
and overexpression of certain miRNAs act as major contributors for SLE susceptibility. These 
epigenetic modifications could either be due to environmental triggers or genetic inheritance 
[125], [126]. Smoking has been shown to have a considerable effect on the disease especially 
on causing active SLE rashes and photosensitivity [127]. Epidemiological data have suggested 
a relationship between EBV infection and SLE incidence as various SLE susceptibility genes 
play important roles in EBV replication and immune evasion [128], [129].   
3.5.3 Pathogenesis of SLE 
The efficient removal of dead cells is a very important process to prevent the 
accumulation of cellular debris which might act as a potential source of auto-antigens. The 
accumulation of cellular debris triggers inflammation followed by leakage of cytoplasmic and 
nuclear auto-antigens such as ribonucleoproteins, DNA, or histones. Phagocytic activity of 
TBMs from SLE patients show a reduced ability to engulf apoptotic material compared to 
healthy donors [130]. The inadequate removal of cellular debris by TBMs in the germinal 
centers (GCs) of secondary lymphoid organs results in release of modified auto-antigens. 
FDCs may present these modified auto-antigens to auto-reactive B cells which results in loss 
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of self-tolerance and auto-antibody production. When autoantibodies are bound to uncleared 
cellular debris in tissues or blood it results in immune complex formation. These immune 
complexes deposit in different tissues such as kidneys, skin, or joints which further leads to 
irreversible organ damage [80], [131]. In addition, studies show that in vitro differentiated MPs 
from SLE patients had reduced and delayed engulfment capacity for autologous apoptotic 
material [132]. Indeed, MPs differentiated from CD34+ HSC and monocytes show reduced 
differentiation and adhesion compared with those derived from healthy individuals [133], [134]. 
Also, peripheral lymphocytes from SLE patients show an increased rate of apoptosis [135]. 
These findings also support the notion that impaired phagocyte function is a primary defect in 
some SLE patients. In addition, anti-ribonucleoprotein autoantibodies detectable in sera of SLE 
patients switch neutrophil death from apoptosis to NETosis [136]. NETosis releases harmful 
intracellular components such as heat shock proteins, HMGB1 or modified histones thereby 
resulting in DC activation [137]. The prevalence of increase in antibodies against NET proteins 
such as defensins or HMGB1 has been previously reported in blood samples from lupus 
patients [138], [139]. These autoantibodies also recognize some components of NETs 
(Neutrophil elastase, Myeloperoxidase, LL-37). The activation of pDCs by these immune 
complexes further result in elevated expression of IFN- regulated genes [140]. This results in 
upregulation of CD80 and CD86 which serves as signal for survival and expansion of 
autoreactive CD4+ autoreactive T cells. Elevated levels of IFN- also lead to upregulation of 
TLR7 which mounts its enhanced response against immune complexes fueling an 
inflammatory loop [141]. During disease progression, tightly regulated apoptosis and necrosis 
turns into a potential source of autoantigens and immunostimulatory signals which is favorable 
to maintain a sustained chronic autoimmune response [142]. 
3.5.4 Complement deficiencies and SLE 
The importance of complement pathways in the immunopathogenesis of lupus and 
other autoimmune disorders was shown many years ago [143], [144]. The complement system 
consists of proteins which can be activated either directly by pathogens or by pathogen bound 
antibodies. The complement proteins of each pathway interact with each other and results in 
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complement activation. As a consequence, pathogens are killed either directly or by facilitating 
phagocytosis and inflammatory responses. There are three pathways of complement 
activation as follows: classical, lectin and alternative cascades which serve to clear pathogens. 
The classical pathway is activated when the C1q complex (C1q, C1r, C1s) interacts with 
immune complexes or when C1q binds to the pathogen surface. The lectin pathway is initiated 
when mannose binding ligand (MBL) or ficolins bind to carbohydrate moieties on pathogen 
surfaces [145], [146]. The alternative pathway is activated during spontaneous hydrolysis of 
C3 or via properdin [147]. Complement proteins exert their effects against infection by either 
promoting phagocytosis of complement coated particles or by promoting inflammation through 
complement factor cleavage products. They also exert their effect directly on pathogens 
causing lysis by forming the membrane attack complex [148], [149]. 
C1q is a soluble macromolecule which has six subunits with each subunit composed 
of three unique polypeptide chains (A, B, C). Members of the classical and lectin complement 
pathway (C1q, adiponectin, MBL, ficolins) share similar structural features such as: a carboxyl 
globular head region, and an extended N-terminal collagen like sequence [150]. The globular 
C1q head binds directly to PS-exposed on apoptotic cells and promotes phagocytosis [151], 
[152]. In addition, C1q also binds to immune complexes, bacteria, virus, DNA, myelin and          
-amyloid [145], [153], [154]. C1q is expressed by cells that are derived from monocyte/MP 
lineage, microglia and DCs [155], [156]. It has also been shown that C1q binds many immune 
cells such as  B cells, monocytes, MPs, DCs, neutrophils [157]–[161]. cC1qR, LRP-1/CD91, 
CR1/CD35, 21, CD93/C1qRp and gC1qR are the identified C1q receptors to date [161]–
[166] (Fig. 3.7). The various C1q dependent apoptotic cells engulfment pathways are shown 
in Figure 3.7. 
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Figure 3.7: Model depicting C1q-dependent engulfment pathways. C1q enhances phagocytosis through following three 
mechanisms. 1) Activation of classical component pathway on the apoptotic cells surface leads to deposition of complement 
opsonin (iC3b and C3b) which further leads to uptake by Complement receptor (CR). 2)The engulfment of apoptotic cells is 
enhanced by deposits of C1q. 3) C1q triggers the expression of Mer tyrosine kinase and GAS6, resulting in engulfment of 
apoptotic cells. Figure is adapted from [146]. 
 
The disease incidence varies between classical complement deficiencies. The 
homozygous C1q deficiency is the highest single gene risk factor known, with more than 90% 
of the affected individuals developing SLE. C1q is considered as a strong opsonin for 
phagocytosis of apoptotic cells and late necrotic cells. The importance of C1q in effective 
uptake of degraded chromatin by monocyte-derived phagocytes was also shown [167]. 
Although homozygous C1q deficiencies are rare, many SLE patients without C1q gene 
mutation also have been reported to have reduced serum C1q activity due to increased 
consumption, reduced production or neutralization by anti-C1q autoantibodies. About 53-92% 
of SLE patients are reported to have low C1q levels in the serum [168]. It has been also shown 
that C1qa-/- mice exhibit increased levels of antinuclear antibodies, develop glomerulonephritis 
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and accumulate apoptotic bodies in the kidneys. However, the genetic background of the mice 
plays an important role in SLE susceptibility [169], [170]. C4 and C2 deficiencies show a lower 
disease incidence [171]. Though the incidence of C4 and C2 is low, it is unclear why their 
deficiency results in a SLE phenotype such as glomerulonephritis and recurrent bacterial 
infection [172], [173]. Only a very few cases of SLE patients were reported to have a C3 
deficiency. In line with this no disease manifestations are seen in C3 deficient mice on a mixed 
129xC57BL/6 background. This further shows that C3 is not critical for SLE development [174]. 
Deficiency of the late complement components C4-C9 is only rarely associated with SLE cases 
but these patients are more prone to develop recurrent bacterial infections [175]. 
There are number of murine models used to study the cellular and genetic requirements 
for SLE induction. The spontaneous lupus models include the F1 hybrid (NZB/WF1) generated 
between the New Zealand Black (NZB) and New Zealand White (NZW) strains. Other 
spontaneous lupus model is MRL/lpr developed from several inbred strains. From initial MRL 
sub-strain characterization, MRL/lpr mice displayed a high mortality rate and unlike the 
NZB/WF1 mice both males and females are affected. The induced lupus models include 
pristine-induced model and chronic graft-versus-host-disease models [176]. These murine 
models also exhibit autoimmune phenotype whereby free nucleosomes including DNA and 
histones were detected similar to active SLE patients [177], [178]. As discussed earlier, NETs 
are a rich source of DNA and are more prone to DNASE1 degradation. Some SLE patients 
show reduced DNASE1 function due to the presence of anti-DNASE1 antibodies or genetic 
variations. A proper co-operation between DNASE1 and C1q is necessary for effective removal 
of necrosis derived remnants [171], [179]. So, deficiency of C1q might prevent the access of 
DNASE1 to NETs resulting in uncleared apoptotic remnants which increases the exposure of 
modified autoantigens to the immune system [180]. pDCs are also stimulated by NET-derived 
immune complexes to release IFN- in a FcRII and TLR-9 dependent pathway [140]. 
3.5.5 Current therapeutic strategies 
SLE is considered as a heterogenous group of diseases in which environmental 
exposures or genetic deficiencies act as a trigger to activate both innate and adaptive immune 
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responses which results in loss of tolerance to self-antigens. There is a long pre-clinical phase 
characterized by accumulation of auto-antibody specificities, followed by inflammation and 
tissue injury. This is followed by onset of clinical symptoms, persistent immune amplification 
and finally irreversible tissue damage. New therapies for SLE are aimed at any of the following 
pathways: Innate immunity, T cells, B cells or tissue injury and inflammation. Many animal 
studies provide valuable information into the therapeutic potential of many experimental drugs 
for SLE. Nevertheless, additional considerations are required when predicting the possible 
outcomes of treatment in SLE patients. There is a huge difficulty in predicting the outcomes 
due to the complex pathogenesis, heterogeneous clinical manifestation of SLE and 
inadequacy in clinical trial design [123]. Patients with refractory SLE are treated with a B cell 
depleting chimeric anti-CD20 antibody which temporarily depletes B cells as well as short lived 
plasma cells [181]. Belimumab is a monoclonal antibody which specifically targets the B cell 
stimulator protein (BLys) thereby preventing the binding of BLys to receptors on B lymphocytes 
which is important for its survival and has been currently approved for SLE treatment [182]. 
Another approach uses Tocilizumab, a monoclonal antibody which targets IL-6 receptor and 
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3.6 Study motivation 
Despite substantial evidence supporting the crucial role of C1q in apoptotic cell clearance 
the exact mechanism by which C1q-deficiency causes lupus remains to be explored. It is known 
that C1q deficiency results in SLE as described earlier, however, the mechanisms in SLE 
development are still ambiguous. This ambiguity in establishing a relationship between C1q 
deficiency and lupus development is addressed by two hypotheses. According to waste disposal 
hypothesis, C1q plays an important role in the prevention of autoimmunity by disposal of dying 
cells and failure of this mechanism would lead to autoantigen driven autoimmunity [148], [149]. 
On the other hand, C1q has been shown to play a role in the induction of tolerance to autoantigens 
[184]. So, during a C1q-deficiency the normal tolerance mechanism is disturbed thereby favoring 
SLE induction.  
The main aim of the project was to identify the mechanisms how C1q deficiency 
contributes to lupus. Therefore, C1q-/- mice were used as a model to study the disease 
mechanisms and to identify susceptibility factors for SLE development. To this end an unbiased 
proteomic screen was performed to identify proteins that were important to disease pathogenesis 
in C1q-KO mouse model. As a result, the identified proteins which might contribute towards 
disease development were investigated further. 
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4 MATERIALS AND METHODS 
4.1 Materials  
4.1.1 Devices 
Devices Company 
Analytic scale Adventurer, Ohaus Corp., Pine Brooks, NJ, USA 
Chemical scale Kern, Albstadt, Germany 
Automatic pipettors Integra Biosciences, Baar, Switzerland 
Pipettes Gilson, Middleton, WI, USA 
Power supply Amersham Pharmacia, Piscataway, NJ, USA 
Water bath Grant Instruments Ltd., Barrington Cambridge, UK 
Vacuum pump KNF Neuberger, Munzingen, Germany 
Vortex-Genie2 Scientific Industries, Bohemia, NY, USA 
Magnetic stirrer Ika Labortechnik, Staufen, Germany 
Tissue homogenizer 
FastPrep-24, MP Biomedicals, Santa Ana, CA, 
USA 
Centrifuge  Rotixa RP, Hettich, Tuttlingen, Germany 
Bench centrifuge Centrifuge 5415 D, Eppendorf, Germany 
pH-meter Inolab, Weilheim, Germany 
Incubator 
Hera cell, Heraeus Kendro Laboratory Products, 
Hanau, Germany 
Laminar airflow cabinet Heraeus, Hanau, Germany 
PCR-machine Biometra, Goettingen, Germany 
Real-time PCR machines 
CFX96 Real Time System, BIO-RAD, Hercules, 
CA, USA 
ELISA-reader 
𝜈max kinetic microplate reader, Molecular 
Devices, Biberach, Germany 
Cell counter 
CASY cell counter and analyzer, OMNI life 
science, Bremen, Germany 
Flow cytometer 
FACSCalibur, FACSCantoII, FACSAria Fusion, 
AMNIS ImageStream BD, Heidelberg, Germany 
Gel Electrophoresis BIO-RAD, Hercules, CA, USA 
Western blot developer Optimax 




4.1.3 Chemicals and buffers 
Unless stated otherwise, chemicals were purchased from Merck (Darmstadt, 
Germany), Roth (Karlsruhe, Germany) or Sigma-Aldrich (St. Louis, MO, USA). All buffers and 
solutions were prepared using double distilled water. 
 
Buffers and Solutions Composition 
PBS 150 mM NaCl 
Items Supplier 
BD Microtainer BD, Franklin Lakes, NJ, USA 
Disposable cell strainer (100 𝜇m nylon) 
Falcon a Corning Brand, 
One Riverfront Plaza, Corning, USA 
Disposable injection needle (26 G x ½”), 
(23 G X ½”), (21 G x ½”) 
Terumo Medical Corporation, Tokyo, Japan 
Disposable syringe (1+5+20 ml) Reaction Braun, Melsungen, Germany 
Disposable MACS filters Milltenyi Biotech 
Disposable MACS columns Milltenyi Biotech 
Disposable glass Pasteur pipettes  VWR International bvba, Leuven, Belgium 
Serological pipette, sterile (10 ml) Greiner, Frickenhausen, Deutschland 
TipOne filter tips (10 𝜇l, 200 𝜇l, 1000 𝜇l) STARLAB GmbH, Hamburg, Germany 
Laboratory gloves Latex Gentle Skin Grip Meditrade GmbH, Kiefersfelden, Germany 
PCR strips tubes (0.2 mL) VWR International, West, Belgium 
qPCR strips tubes (0.2 mL) BIO-RAD 
Reaction container 1.5 ml, 2 ml, 5 ml  Eppendorf, Hamburg, Germany 
Reaction container 5 ml (FACS) BD, Franklin Lakes, NJ, USA 
Petri dish  Greiner Bio-One GmbH, Germany 
Tissue culture plates (96 wells-U, 6 and 
12 well sterile) 
VWR International bvba, Leuven, Belgium 
Tissue culture flasks (T25, T75 and T175) Nunc 
8-well chamber glass slides Nunc, Lab-Tek 
Lysing matrix tubes (matrix D) 
MP Biomedicals Germany GmbH, Eschwege, 
Germany 
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10 mM Na2HPO4 
 2 mM KH2PO4 
 pH 7.4 adjusted with 5 N NaOH 






0.5 % FCS, 2 mM EDTA 
ACK Lysis Buffer 
 
8.29 g NH4Cl 
1 g KHCO3 
37.2 mg Na2EDTA 
H2O add 1 lt 
pH 7.2-7.4 adjusted with HCl 
sterilized by 0.2 μm filtration 
10x Gitocher Buffer 
 
670 mM Tris, pH 8.8 
166 mM ammonium sulfate 
65 mM MgCl2 
 0.1 % Gelatin 
5x Cresol Red Buffer 
 
250 mM KCL 
50 mM Tris/HCL pH 8.3 
43 % glycerol 
2 mM Cresol-red 
7.5 mM MgCl2 
50x TAE Buffer 
242 g Tris 
57.1 ml 100 % acetic acid 
100 ml 0.5 M EDTA (pH 8.0), H2O add 1 lt 
SDS Running Buffer 
 
192 mM Glycin 
25 mM Tris 
0.1 % SDS 
Separating Gel 12% 
H2O (6.6 ml) 
30 % acrylamide mix (8 ml) 
1.5 M Tris/HCL, pH 8.8 (5 ml) 
10 % SDS (200 μl) 
10 % ammonia persulphate (200 μl) 
TEMED (20 μl) 
Stacking Gel 5% 
H2O (2.1 ml) 
30 % acrylamide mix (500 μl)) 
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1 M Tris/HCL, pH 6.8 (380 μl) 
10 % SDS (30 μl) 
10 % ammonia persulphate (30 μl) 
TEMED (3 μl) 
Cell culture medium 
DMEM Medium (GIBCO) 
10 % FCS 
100 U/ml Penicillin 
RIPA Lysis buffer 
1M NaCl 
1% Nonident P-40 
0.5% Sodium deoxycholate 
0.1% SDS 
50 mM Tris, pH 7.4 
Transfer buffer 
192 mM Glycine 
25 mM Tris 
20 % Methanol 
0.002 % SDS 
Stripping buffer  
 
62.5 mM Tris 
pH 6.7 adjusted with HCL 
100 mM β -mercaptoethanol 
2 % SDS 
10x TBS 
0.2 M Tris base 
1.5 M NaCl 
pH 7.4 adjusted with HCl 
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4.1.3.1 Immunofluorescence 
Buffers Composition 
Fixation buffer 4% PFA in 1x PBS 
Blocking buffer 4% BSA in 1x PBS 
Permeabilizing Buffers 
(Based on antibody compatibility) 
 
100% Methanol 
0.1% TRITON-X in 1x PBS 
0.05% Saponin in blocking buffer 
0.1% Saponin in blocking buffer 
 
4.1.3.2 Proteomics buffers 
Buffers Composition 
Lysis buffer 1 
100 mM TRIS, pH 7.6 
6 M urea 
2 M thiourea 
30 mM DTT 
Phosphatase inhibitor (Roche) 
Lysis buffer 2 
100 mM TRIS, pH 7.6 
20 mM Iodoacetamide 
2 mM Cacl2 
25 mM NaCl 
 
4.1.4 FACS antibodies 
Epitope Conjugate Clone Supplier 
CD3e PE 145-2C11 e-Bioscience 
CD19 FITC 1D3 BD Pharmingen 
CD45R FITC 30-F11 Biolegend 
CD16/32 unconjugated 2.4G2 BD Bioscience 
CD11b APC-Cy7 M1/70 e-Bioscience 
F4/80 APC BM8 e-Bioscience 
MFGE8 Biotin - Novus Biologicals 
Streptavidin APC - BD Bioscience 
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4.1.5 Western blot antibodies 
Specificity Host Dilution Supplier 
DNASE2A Rabbit 1:1000 LS Biosciences 
-ACTIN Rabbit 1:1000 CST 
-TUBULIN Mouse 1:1000 CST 
IRF3 Rabbit 1:1000 Abcam 
pIRF3 Rabbit 1:1500 CST 
TBK1 Rabbit 1:1000 Abcam 
pTBK1 Rabbit 1:1000 CST 
STING Rabbit 1:1000 Abcam 
Anti-rabbit HRP Donkey 1:2500 Jackson Lab 
Anti-rat HRP Donkey 1:2500 Cell Signaling 
Anti-mouse HRP Donkey 1:2500 Jackson Lab 
Anti-goat HRP Donkey 1:2500 Jackson Lab 
4.1.6 Immunohistochemistry antibodies 
Specificity Host Dilution Supplier 
RAB5 Rabbit 1:100 CST 
LAMP1 Rat 1:1000 BD Biosciences 
LysoTracker DND-99  - 1:3000 Molecular Probes 
DAPI - 1:1000 Bio Legend 
TFEB Rabbit 1:200 BioMol 
Anti-rabbit IgG(H+L) - 1:600 Molecular probes 
Anti-rat IgG (H+L) - 1:600 Molecular probes 
Anti-mouse IgG (H+L) - 1:600 Molecular probes 
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4.1.7 Mouse strains 
C1q-KO (C1qatm1Mjw) were bred on a (129x1/SvJ), F2 mixed background. B6129 
(C57BL/6 x 129) were used as wild-type for all experiments. All mice were analyzed in sex and 
age-matched groups of 12-16 weeks of age. The SPF-status of the facility was tested 
according to the Federation for Laboratory Animal Science Association (FELASA) 
recommendations. Animal experiment permissions were granted by the animal ethics 
committee of the Regierung von Oberbayern, Munich, Germany. All mice were bred and 




4.2.1 Immunological and cell biology methods 
4.2.1.1 Harvest of blood and organs 
Animals were euthanized in a CO2 chamber for harvesting pMPs and thymus. For 
harvest of spleens mice were euthanized by cervical dislocation after they had been sedated 
using isoflurane. Organs were removed using scissors and fine tweezers following which they 
were placed in FACS Buffer. For harvesting pMPs, a small incision in the center of the skin 
overlying the peritoneal wall is made. Afterwards 10-12 ml of PBS was injected into the 
peritoneum using a 20 ml syringe with a 25 g needle. After a brief massage for approximately 
20 seconds a syringe with 20 g needle is inserted into the peritoneal membrane avoiding 
insertion into gut, fat or mesentery regions. About 8-10 ml fluid is recovered from each mouse 
and placed on ice. Spleens were removed from mice and smashed through a 100 m cell 
strainer and washed with ice cold FACS buffer. Red blood cells were lysed using 1 ml of ACK 
buffer for 5 min at room temperature. Samples were washed once again, counted with CASY-
counter (OMNI Life science, Bremen, Germany) and stored on ice for further analysis. 
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4.2.1.2 Flow cytometry – Fluorescence activated cell sorting (FACS) 
Flow cytometry is a method used for the evaluation of various characteristics of single 
cells based on size, granularity and molecular markers. Cells are stained with fluorochrome 
coupled antibodies against cell surface or intracellular antigens. When cells pass in a fluid 
stream through a laser beam and several detectors certain information is obtained which can 
be further used for identification of distinct cell populations from a heterogenous mixture of 
cells. Data acquisition was performed using FACS Canto.  
An improvement to classical flow cytometry is cell sorter (FACSAria, BD) in which the 
cell population of interest is defined and further collected by electrostatic droplet deflection. 
These sorted cells were further used for further analysis. Another additional improvement to 
flow cytometry is Image stream flow cytometry which combines features of flow cytometry and 
microscopy. The output files obtained can be used to categorize each cell types and also 
microscopic images of cell type at the same time. ImageStreamX Mark-II (Amnis Corporation, 
Seattle, WA, USA) is equipped with 5 lasers (405 nm, 488 nm, 561 nm, 642 nm and 785 nm) 
and is also capable of detecting side scatter and bright field. The raw data is obtained by Amnis 
INSPIRE and further analyzed by IDEAS software. The different cell populations are 
discriminated based on several features such as size, shape and fluorescent intensities.  
For flow cytometric analysis equal cell numbers were plated onto a 96 well plate. Cells 
were washed once with 200 l FACS buffer and stained for 25 min at 4 C in dark using 100 l 
of antibody mix prepared in FACS buffer. Every antibody has been titrated before use and an 
antibody with minimal signal to noise ratio is chosen for further experiments. After incubation 
cells are washed thrice with 200 l FACS buffer and used for FACS acquisition immediately. 
For AMNIS acquisition cells were fixed with Cytofix/Cytoperm (BD Biosciences) for 20 min 
followed by washing twice in 1x Perm Wash Buffer (BD Biosciences). Cells were stained for 
intracellular markers followed by fixation and permeabilization in some cases. Data analysis 
was performed using FlowJo version 9 or 10 (TreeStar, Ashland, OR, USA). 
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4.2.1.3 Magnetic cell sorting (MACS) 
MACS is a technique used to separate cell populations based on their surface markers 
using magnetic beads linked to monoclonal antibodies. This technique can be used either for 
depleting or enriching required cell type. Cells are incubated with respective magnetic beads 
(CD3e Biotin, CD19, CD11b) followed by washing with MACS buffer to remove unbound 
beads. After labelling, cells are loads onto the respective magnetic column (Depletion – LD 
Columns and Enrichment – LS Columns). Labeled cells are retained in the magnetic columns 
while unlabeled cells (negative fraction) pass through the column which is also collected. The 
positive fraction is collected by applying pressure with the help of a provided plunger. In either 
case columns are rinsed thrice for collecting respective fractions. This technique was used for 
depleting T cells (CD3), B cells (CD19) from spleen and enriching MPs (CD11b) from the 
peritoneum. All procedures were performed according to manufacturer instructions without any 
modifications. 
4.2.1.4 Immunofluorescence staining 
For immunostaining, the flushed out pMPs were cultured on an 8-well chambered glass 
slides (ThermoScientific) for 3 hours at 37C, 5 CO2 which allows the MPs to adhere better. 
The cells were then washed with 1x PBS for three times to remove non-adherent cells. The 
samples were later fixed for 15 minutes with 4% paraformaldehyde followed by washing with 
1x PBS thrice. The samples were permeabilized using 0.1% Triton-x for 10 min (RAB5), 0.05% 
Saponin for 30 minutes (LAMP-1) and 100% Methanol for 5 minutes (TFEB) followed by 
washing thrice with 1x PBS. All samples are blocked using 1x Blocking buffer (4% BSA in 1x 
PBS) for 1 hr. Without any washing steps cells were incubated overnight at 4C with respective 
primary antibody resuspended in 1x Blocking Buffer. The samples were washed four times 
with 1x PBS and incubated for 1hr at room temperature with corresponding secondary 
antibody. The samples are taken for mounting after washing four times with 1x PBS. All staining 
was performed in a moist chamber and at dark conditions. Slides were mounted with Prolong 
gold-antifade reagent (Thermo Fisher Scientific) and viewed at 22C on a ZEISS confocal 
laser-scanning LSM 780 microscope equipped with 100x (NA 1.46 oil) objective. Pictures were 
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acquired using Leica software (ZEN 2010) and processed, merged and gamma adjusted in 
ImageJ (version 10.2).  
4.2.1.5 Apoptosis induction 
HeLa spinner cells and mcherry tagged to Histone (H2B) HeLa cells were used as a 
source of apoptotic material for all experiments. mCherry-H2B HeLa cells were provided by 
Andreas Ladurner Lab [185], Department of Physiological Chemistry, LMU. These cells were 
cultured using DMEM supplemented with 10% FCS and Penstrap antibiotics grown in 
T75/T175 cell culture flasks (37C, 5% CO2). Adherent cells are recovered from confluent 
flasks using 1x PBS supplemented with 2mM EDTA. Apoptosis is induced by adding 
Staurosporine (1g/ml) and incubating cells for three hours. Cells are washed thrice in 1x PBS 
and later used as apoptotic material to inject mice. 
4.2.1.6 in vivo Phagocytosis assay 
Apoptotic cells (8x106 – 10x106) prepared as above is injected intraperitoneally (i.p) to 
experimental mice. pMPs were harvested following 3 hours, 6 hours and 12 hours following 
apoptotic cell injection. The cells are later stained and fixed for flow cytometry acquisition. For 
analyzing mRNA expression, flushed out peritoneal cells were CD11b+ enriched using MACS 
and further stored in TRIzol. 
4.2.2 Molecular Biology 
4.2.2.1 mRNA isolation and cDNA conversion 
Tissue samples and cells (MACS depleted or enriched) were lysed in 1.5 ml of TRIzol 
(SIGMA) and RNA was isolated using Phenol-Chloroform extraction twice followed by 
precipitation of RNA with isopropyl alcohol. Next 1 g of total RNA was transcribed to cDNA 
using Reverse transcription kit (Qiagen) and later used for qPCR analysis. 
4.2.2.2 Quantitative PCR (qPCR) 
qPCR is used to quantify the changes at gene level and is performed using the SYBr 
green SensiMix (Bioline) on a CFX96 Touch Real-Time PCR detection system (BioRad). 
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GAPDH was used as the house keeping gene for normalization. In a 96 well plate 10 l of 
cDNA (1:100) was mixed with 12.5 l 2x-concentrated SensiMix, 0.125 l of forward and 
reverse primer (100 M) and 2.25 l RNase free water. The SensiMix master mix containing 
StarTaq DNA Polymerase, SYBr Green I dye, reaction buffer and nucleotides (dATP, dCTP, 
dGTP, dUTP). All samples were amplified in triplicates.  
The cycling conditions were as follows:  
Step 1: Denaturation at 95C for 10 minutes 
Step 2:  95C for 10 seconds 
Step 3: Primer annealing at 60C for 10 seconds 
Step 4: Extension at 72C for 10 seconds 
Step 2 – 4: Repeated 40 cycles 
 
The qPCR raw data obtained were quantified using 2n technique by normalizing the gene 
expression of housekeeping GAPDH gene. The list of primers used in this study is listed in 
Appendix 9.3. 
4.2.2.3 SDS PAGE and western blot 
Cells for western blot were washed once with 1x PBS to remove extracellular proteins, 
pelleted and resuspended at a concentration of 1x106 cells per 10 l of RIPA Lysis buffer. To 
prepare spleen lysates for western blot, weight of spleen is measured and RIPA lysis buffer in 
the presence of protease (Roche) and phosphatase inhibitors (CST) according to tissue weight 
was added in a vial containing Matrix-D beads. The tissue samples were homogenized in a 
homogenizer at 6 M/s for 40 seconds. The supernatant from both cases is freeze thawed thrice 
using liquid nitrogen and centrifuged at 12000 rpm at 4C to remove cellular any debris present. 
The protein concentration of cell lysates was quantified using BCA assay (Pierce). Equal 
amounts of protein were then denatured using sodium dodecyl sulfate (SDS) at 95C for 5 
minutes and further used for SDS-PAGE. 
Equal amounts of protein were loaded onto a 12% SDS gel prepared and proteins are 
separated by gel electrophoresis for 2 hours at 80-100 V. PageRulerTM prestained marker was 
used to confirm the approximate size for the protein of interest. Separated proteins were later 
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transferred onto a nitrocellulose membrane (Amersham) using a wet transfer system (BIO-
RAD) at 80 V for 90 minutes. Membranes were blocked in 5% milk powder in TBS 
supplemented with 0.5% Tween-20 (Blocking buffer) for 1 hour at room temperature with gentle 
shaking. Membranes were later washed once with 1X TBST followed by incubation with 
primary antibody overnight resuspended in 5% BSA resuspended in 1x TBST. Membranes 
were washed for (4x10 minutes each) in 1x TBST followed by incubation in corresponding 
secondary antibody resuspended in blocking buffer for 90 minutes. Once again membranes 
were washed for (4x10 minutes each) in 1x TBST. Membranes were developed using 
enhanced chemiluminescence (ECL) western blot substrate (PerkinElmer Inc., MA, USA) 
followed by exposure to Amersham HyperfilmTM (GE Healtcare). The relative protein 
expression was quantified by normalizing either to -actin or -tubulin as mentioned in figure 
legends. The quantification was performed using the free online tool ImageJ. 
4.2.2.4 Sample preparation for proteomics 
 4.2.2.4.1 Spleen 
To induce germinal center responses 6-8 weeks mice were immunized intravenously 
with 2x108 sheep red blood cells (SRBC), a T cell dependent antigen, in PBS on day 0 and 
analyzed on day 7. Spleen from SRBC immunized mice with four biological replicates. 
Depletion of B cells and T cells was performed using magnetic anti-CD19 and anti-CD3 
microbeads (MACS Miltenyi Biotech). Samples were analyzed on an LC-MS/MS setup 
coupling a Proxeon Easy nLC11 to a Q-Exactive mass spectrometer. In-house packed 25 cm 
emitter columns and a bilinear 120 min gradient was applied for peptide separation. Eluted 
peptides were fractionated using the StagTip-based SAX fractionation technique into three 
fractions with pH 11, 6 and 3. For protein identification and quantification, the MaxQuant 
software suite was used and data was obtained by relative quantitation of ion-peak intensity. 
The expression levels of protein were computed as the mean of the LFQ values for all the 
proteins from WT spleens. The LFQ values from the C1q-KO mice were divided by this mean 
of the WT spleen samples for the respective protein to scale the knock-out LFQ values. The 
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proteomics was performed by Bastian Dislich from Stefan Lichtenthalers’s group at the DZNE 
Munich. 
4.2.2.4.2 pMPs 
pMPs are flushed as mentioned before in section and stained for CD19, CD11b and 
F4/80 surface markers followed by FACS sorting of CD19-F4/80+ CD11b+ cells. Cells were 
disrupted using 50 l of Lysis buffer1(recipe in 4.1.3) by sonicating in a covaries sonicator 
using cycles of 30 sec pulse and 30 sec cooling for 10 minutes. Subsequently, samples were 
incubated at 28C for 1h to allow the disulfide bond reduction. For initial digestion of proteins 
at 28C, 3 g LysC was used with slow agitation for 4 hrs. Subsequently, sample was diluted 
with 250 l of Lysis buffer2 (recipe in 4.1.3) and to ensure complete proteolytic digestion, 10 
g trypsin was added and incubated for 12 hrs with slow agitation at 900 rpm. Samples were 
acidified by adding formic acid (FA) containing 10% trifluoroacetic acid to a final concentration 
of 4% FA, pH 2 to 3. Eluting peptides were ionized in a NanoESI source and detected on an 
QExactive HF mass spectrometer (ThermoFisher Scientific). The mass spectrometer was 
operated in a TOP10 method with positive ionization mode, detecting eluting peptide ions in 
the m/z range from 300 to 1600 and performing MS/MS analysis of up to 10 precursor ions per 
cycle. Peptide ion masses were acquired at a resolution of 60000 (200 m/z); higher-energy 
collision-induced dissociation (HCD) MS/MS spectra were acquired at a resolution of 15000 (at 
200 m/z). The proteomics was performed by Andreas Schmidt from Axel Imhof group at the 
Protein analysis unit, Biomedical Center Munich. 
4.2.2.5 Label-free quantification 
All MS raw data were searched against a combined forward/reversed protein database 
of Mus musculus by the Andromeda search engine within the Max Quant (vs. 1.5.5.1) software 
suit. For peptides the mass accuracy was set to 20 ppm for the first search, 5 ppm for the main 
search, 20 ppm for fragment ions was applied. Peptides with a maximum of 2 missed 
cleavages for Trypsin/P, a minimal score of 10 for unmodified peptides and 35 when carrying 
post-translational modifications were considered. Carbamidomethylation of Cys was set as a 
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fixed modification, putative variable modifications were oxidation (M), acetylation (Protein N-
term), and phosphorylation (STY). These peptide spectrum matches were filtered for 1% FDR 
rate and the resulting protein hits were again filtered for 2% detection of reversed sequences. 
Proteins were quantified and considered for further analysis only when at least 2 peptides were 
detected. The resulting intensity values were converted to iBAQ values to compensate for 
protein sequence differences. LFQ intensities were log2 transformed and compared between 
WT and C1q-KO using a modified student’s t-test. In order to correct for multiple hypothesis 
testing, an FDR rate of 5% calculated by sample permutation was applied. 
4.2.2.6 Cloning and Protein purification 
Murine MFGE8-DNASE2A was produced from stably transfected HEK293 cells. Cells 
were grown in a Labfors Bioreactor (Infors, Switzerland) in serum-free medium (Ex-Cell 293, 
Sigma) for 5 days. Cells were removed from the cell culture supernatant (SN) by centrifugation 
(300g, 10 minutes). 0.1% Triton-X 100 was used to solubilize membrane proteins. SN was 
incubated under agitation for 1 hr. Debris was cleared by high-speed centrifugation (40.000g, 
60 min) and filtration (0.2 um). MFGE8-DNASE2A was then purified by FLAG affinity 
chromatography using M2-FLAG agarose beads (Sigma). Bound protein was eluted using a 
FLAG-peptide (Genscript, China). The eluate was concentrated using spin columns with a 
cutoff of 30-kDa (Sartorius).  
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Figure 4.1 MFGE8-DNASE2A cloning strategy: Mfge8 and DNase2A is digested using compatible restriction 
enzymes and cloned into pcDNA 3.0 -globulin vector together with FLAG tag. The whole construct is transfected to 
HEK cells and further stabilized and purified using FLAG tag. 
 
4.2.2.7 Agarose gel electrophoresis 
Agarose gel is used to visualize, and separate DNA fragments based on size. The 
agarose gel was prepared by dissolving 1-1.5% (w/v) agarose in TAE buffer, depending on the 
molecular size of the fragment of interest. As a reference and to predict the fragment size either 
a 100 bp or a 1 kb ladder was used (New England Biolabs, Ipswich, MA, USA). Loading buffer 
(10% glycerol, Xylene cyanol FF) was added before loading the sample to the gel. DNA 
samples were visualized using ethidium bromide (0.5 g/mL) that was added during agarose 
gel preparation followed by visualization and documentation in Gel DocTM (BIO-RAD). 
4.2.2.8 Statistics 
Significance was performed using PRISM Software (GraphPad Software, La Jolla, CA, 
USA). All bar graphs are represented as average ± standard error of the mean (SEM) from 
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single or combined experiments as indicated in the figure legends. The significance was 
analyzed using the students t-test and defined as follows: *p = 0.01 - 0.05, **p = 0.001 – 0.01 
and ***p < 0.001.  
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5 RESULTS 
5.1 Does C1q deficiency affect phagocytosis pathways? 
5.1.1 in vivo tracking of apoptotic cells 
It has been reported earlier that peritoneal macrophages (pMPs) from C1q-KO mice 
have an early uptake defect of apoptotic cells in vitro [186]. To investigate the influence of C1q 
on phagocytosis, apoptotic HeLa cells were injected into wild-type (WT) and C1q-KO mice. 
The peritoneal cavity is an ample source of macrophages (MPs), thus ideally suited to study 
phagocytosis pathways in vivo. The tracking of injected mcherry-HeLa cells is possible, as the 
H2B-histones of HeLa cells are fluorescently labelled with mCherry. This allows us to visualize 
non-degraded nuclear material inside MPs. The apoptotic cells were administered 
intraperitoneally (i.p.) and pMPs were harvested following 3 hours, 6 hours and 12 hours (Fig. 
5.1A). For imaging flow cytometric analysis, pMPs containing engulfed apoptotic mCherry-
labelled HeLa cells are defined as B220-CD19-CD11b+mCherryint cells and unengulfed 
apoptotic cells as B220-CD19-CD11b-mCherryhigh cells (Fig. 5.1B). 
We found no significant difference between WT and C1q-KO mice in the frequencies 
of CD11b+mCherryint after 3 hours of phagocytosis. However, we observed that the frequency 
of CD11b+mCherryint cells was significantly increased at least by three-fold in C1q-KO mice as 
compared to WT mice after 6 hours of phagocytosis (p = 0.01). Similarly, there was a two-fold 
increase in the frequency of CD11b+mCherryint cells in C1q-KO mice compared to WT after    
12 hours of phagocytosis (p = 0.09) (Fig. 5.1B, upper panel). The total frequency of 
CD11b+mCherryint cells in WT and C1q-KO mice following 3 hours, 6 hours and 12 hours of 
phagocytosis is quantified and shown (Fig. 5.1C, left panel). The persistence of phagocytosed 
material inside the MPs of WT and C1q-KO mice upon 6 hours of phagocytosis was also 
confirmed by images obtained from imaging flow cytometry (Fig. 5.1D). 
 





Figure 5.1 in vivo phagocytosis assay WT and C1q-KO mice  
 
A. WT (n = 4) and C1q-KO mice (n = 4) were injected with apoptotic mcherry HeLa cells. In addition, WT (n=1) was injected 
with unlabeled HeLa cells as control. pMPs were flushed following 3 hours, 6 hours and 12 hours of in vivo phagocytosis 
assay. Single cell suspension of harvested peritoneal washes was stained and fixed for acquisition on image stream flow 
cytometry. 
B. The upper panel shows representative FACS plots for CD11b+mCherryint pMPs which have taken up mCherry tagged 
apoptotic cells following 3 hours, 6 hours and 12 hours of in vivo phagocytosis. Cells are gated on live B220-CD19- cells. The 
lower panel shows representative FACS plots for mCherryhigh cells (unengulfed cells) gated on all cells. The FACS plots of 
one out of two independent experiments (n = 4 animals per group) is shown. 
C. The frequency of CD11b+ mCherryint (left panel), MFI of CD11b+ mCherry+ (right panel) and mCherry+ as unengulfed cells 
(middle panel) is quantified and shown. Statistically significant differences between WT and C1q-KO mice: *p < 0.05, not 
significant (ns). 
D. Representative Imagestream flow cytometric images showing the co-localization of mCherry-labelled HeLa cells within 




The unengulfed CD11b-mCherry+ cells represent the injected apoptotic mCherry HeLa 
cells which were not taken up by the MPs (Fig. 5.1B, lower panel). There was a significant 
increase in the frequencies of CD11b-mCherryhigh unengulfed cells after 3 hours (p = 0.04) and 
6 hours (p = 0.02) indicating a delayed uptake of apoptotic cells in C1q-KO mice (Fig. 5.1B, 
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persisted after 12 hours in C1q-KO mice which further supported the notion that there was an 
uptake defect of apoptotic cells (Fig. 5.1B, lower panel, 12 hours). The frequencies of 
mCherryhigh unengulfed cells following 3 hours, 6 hours and 12 hours is quantified and shown 
(Fig. 5.1C, right panel). Taken together these results not only confirm the previously reported 
uptake defect of apoptotic cells seen from the pMPs of C1q-KO mice [186], but also indicate 
an impaired degradation of nuclear material derived from phagocytosed apoptotic cells. 
5.1.2 An unbiased proteomics screen 
Having confirmed the phagocytosis defect and having identified a previously 
undescribed degradation defect of engulfed nuclear material in C1q-KO pMPs, we sought to 
identify factors responsible for the observed defects caused by C1q deficiency. Therefore, we 
analyzed the whole protein content (proteome) of WT and C1q-KO MPs by performing an 
unbiased label-free proteomics screen. 
5.1.2.1 Spleen Proteomics 
For this, we enriched for phagocytic cell populations of spleens from sheep red blood 
cells (SRBC) immunized WT and C1q-KO mice by depleting B cells and T cells using magnetic 
anti-CD3 and anti-CD19 beads (Fig. 5.2A). SRBC immunization was performed to enhance 
germinal centre responses in the spleen as described earlier [187]. WT and C1q-KO samples 
were analysed separately from each other and resulting data sets were combined for label-
free quantification as described in chapter 4.2.2.4.1. 
From these proteomic analyses, 3738 proteins with at least two unique peptides were 
selected. The fold change values for each identified protein as a ratio of C1q-KO/WT showed 
which proteins were up- or downregulated in cells from C1q-KO mice. About 40 proteins were 
identified as being significantly upregulated, while 50 proteins were downregulated by >30% 
in C1q-KO mice compared to the WT group. To determine differentially regulated proteins, an 
increase, or decrease in the protein level at least by 1.2-fold and a p-value according to 
student’s t-test below 0.05 was chosen (Fig. 5.2B).  
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Figure 5.2 Label free proteomics for identifying differentially regulated proteins in C1q-KO spleen enriched MPs 
 
A. Spleen cells of SRBC immunized WT (n = 4) and C1q-KO mice (n = 4) were depleted of T and B cells to enrich phagocytic 
cells, followed by label-free proteomics. 
B. The differentially regulated proteins in C1q-KO mice are shown by volcano plot where the p-value (in log10 scale) on the y-
axis is plotted against the ratio of protein levels (in log2 scale) on the x-axis. The protein candidates marked red are 
downregulated and green are upregulated by 1.2-fold change. 
C. The bar graph shows fold change values (C1q-KO/WT) + SEM of selected protein candidates in lysosomal compartments 
and V-Type ATPases. Tubulin was used as a housekeeping protein for normalization. Proteins marked with an asterisk are 
significantly regulated candidates.  
 
Within the differentially regulated proteins, we observed a significant downregulation of 
lysosomal hydrolases such as DNASE2A, ASAH1, CTSB and CTSD in splenic MPs of C1q-
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ATP6v1b2 and ATP6v1f (Fig. 5.2C). The list of regulated candidates is provided in Appendix 
9.1. 
5.1.2.2 pMP Proteomics 
We have identified some of the most important lysosomal hydrolases to be significantly 
reduced in a cell suspension enriched for C1q-KO MPs from spleen. Next, we wanted to 
confirm these results from less complex samples and therefore performed an additional 
proteomics screen, using pure pMPs from WT and C1q-KO mice. 
To obtain pure pMPs, cells were stained with anti-CD11b antibodies, purified by FACS 
sorting on an AriaXY and further processed for label-free proteomics (Fig. 5.3A). The purity of 
pMPs obtained following sorting was typically around 93-95%. WT and C1q-KO samples were 
analysed separately from each other and resulting data sets were combined for label-free 
quantification as described in chapter 4.2.2.4.2.  
From these proteomic analyses, 2044 proteins with at least two unique peptides were 
selected. LFQ intensities were log2 transformed and compared between WT and C1q-KO using 
a modified student’s t-test. To distinguish the differentially regulated proteins, an increase, or 
decrease in the protein level at least by 3- fold and p-value according to student’s t-test below 
0.05 was chosen (Fig. 5.3B).  
Again, many lysosomal and endosomal proteins were downregulated in C1q-KO mice, 
such as LAMP1 & LAMP2 and the endosomal trafficking proteins VAMP7 & VAMP8. It was 
also evident that proteins from Rab-GTPases family such as RAB5B, RAB9A, RASSF2 and 
RAB11FIP1 were significantly downregulated in C1q-KO pMPs. In this analysis, we did not 
observe any significant differences in lysosomal hydrolases as we observed in splenic MPs 
(Fig. 5.2). The changes in lysosomal protein composition were obvious in C1q-KO pMPs as 
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Figure 5.3 Label free proteomics for identifying differentially regulated proteins in C1q-KO pMPs 
 
A. CD11b+ pMPs of WT (n = 4) and C1q-KO mice (n = 4) were FACS sorted and processed for label-free proteomics. 
B. Differentially regulated proteins in C1q-KO mice are shown by volcano plot where the p-value (in log10 scale) on the y-axis 
is plotted against the ratio of protein levels (in log2 scale) on the x-axis. The proteins shown in red are downregulated and 
proteins shown in green are upregulated by 3-fold change. 
C. The bar graph shows fold change values (C1q-KO/WT) of selected protein candidates in lysosomal compartments and Rab-
GTPases. Tubulin was used as a housekeeping protein for normalization. 
 
The downregulation of proteins in the endo-lysosomal compartment in C1q-KO MPs 
corroborates the fact that C1q-KO MPs exhibit an uptake defect as published previously. 
Furthermore, such a defect might contribute to the delayed degradation of phagocytosed 
nuclear material observed in this study (Fig. 5.1). The accumulation of nuclear material in C1q-
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KO MPs could be a direct consequence of the reduced DNASE2A levels we detected in the 
spleen of C1q-KO mice. DNASE2A is ubiquitously expressed in lysosomes and exhibits activity 
over a low pH 4.5-5.5 [188]. DNASE2A deficient MPs are unable to digest the DNA from 
apoptotic cells, which thereby accumulates in their lysosomes and activates the production of 
interferons [189],[190]. Since C1q-KO mice exhibit impaired phagocytosis, further investigation 
of DNASE2A levels in these phagocytic cells could provide an insight into disease development 
in C1q-KO mice. Also, studies have shown the importance of RAB5 in establishing a stable 
endo-lysosomal system in phagocytes [191]. Thereby from these two proteomic screen 
DNASE2A, RAB5B and LAMP1 were chosen as potential candidates for further analysis which 
could possibly have a major role in SLE development.  
5.1.3 Confirmation of the proteomics screen 
5.1.3.1 DNase2a expression in WT and C1q-KO spleen enriched MPs and pMPs 
Next, Dnase2a expression levels in C1q-KO mice were quantified at gene levels by 
qPCR and detected by Western blot in spleen enriched MPs and pMPs. The Dnase2a gene 
expression was more than two-fold reduced in C1q-KO MPs enriched from spleen (p= 0.0003) 
and pMPs (p = 0.0009) (Fig. 5.4).  
 
 
Figure 5.4 Gene expression of DNase2a in WT and C1q-KO mice  
WT (n = 4) and C1q-KO mice (n = 4) was used for quantifying DNase2a expression in enriched MPs from spleen (CD3-CD19-). 
WT (n = 5) and C1q-KO mice (n = 5) was used for quantifying DNase2a expression in CD11b enriched pMPs. Statistically 
significant differences between WT and C1q-KO mice: **(p < 0.01), ***(p < 0.05). Data shown here are from one representative 
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Having confirmed reduced DNase2a mRNA levels in C1q-KO MPs, next we analyzed 
DNASE2A expression in pMPs and splenic enriched MPs. It was interesting to analyze 
MFGE8-KO mice because it has been previously shown to exhibit impaired uptake of apoptotic 
cells and develop lupus like autoimmune disease [92], [192]. In addition, we also investigated 
DNASE2A levels in C3-KO because the complement factor C3 acts downstream of C1q even 
though it has been shown earlier that they do not render a protective role against SLE 
development [193]. 
The expression of DNASE2A protein was diminished in pMPs (Fig. 5.5A) and enriched 
MPs from C1q-KO spleen compared to WT (Fig. 5.5B). We detected normal protein levels of 
DNASE2A in enriched MPs from C3-KO and MFGE8-KO spleens. However, the DNASE2A 
expression in total splenocytes remained unchanged in C1q-KO mice (Fig. 5.5C). Therefore, 
above results indicate that the reduction in DNASE2A levels, an important lysosomal hydrolase 
might be specific to C1q-KO MPs. Also, these experiments indicate C1q deficiency leads to 
substantial and significant decrease of DNASE2A protein and DNase2a gene expression 
which warrant further investigation. The reduced DNASE2A expression in C1q-KO MPs 
corroborate with those findings of mice showing delayed degradation of phagocytosed 
apoptotic material as shown earlier (Fig. 5.1). 
Figure 5.5 Protein level Expression of DNASE2A in WT and C1q-KO mice 
A. Western blot showing DNASE2A expression in pMPs of WT (n = 6) and C1q-KO (n = 6) where isolates from three mice 
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B. Western blot showing DNASE2A expression levels in spleen enriched MPs of WT (n = 2), C1q-KO (n = 2), C3-KO (n = 2), 
Mfge8-KO (n = 2).  
C. Western blot showing DNASE2A expression levels in total splenocytes of WT (n = 3) and C1q-KO (n = 3).  
D. The relative expression is quantified with -actin as housekeeping control. Bar graphs show one representative experiment 
out of two with similar trend. 
 
5.1.3.2 Rab-GTPases in WT and C1q-KO spleen enriched MPs and pMPs 
RAB5 is commonly used as a marker for early endosomes, RAB9 for recycling 
endosomes and LAMP1 as a marker for lysosomal compartments [194], [195]. As we found 
the levels of these proteins being decreased in C1q-KO pMPs, we next analyzed gene 
expression by qPCR. While MPs enriched from spleen did not show any significant regulation 
of these genes, pMPs from C1q-KO mice showed more than two-fold down-regulation of Rab5- 
and Rab9-expression, but strong upregulation of Lamp1 (Fig. 5.6). 
 
Figure 5.6 Gene expression of Rab5, Rab7, Rab9 and Lamp1 in WT and C1q-KO mice 
WT (n = 4) and C1q-KO mice (n = 4) were used for quantifying Rab5, Rab9 and LAMP1 mRNA expression in spleen enriched 
MPs (CD3-CD19-) and in CD11b-enriched pMPs. Statistically significant difference between WT and C1q-KO mice: *(p < 0.05), 
**(p < 0.01), ***(p < 0.05), ns – non-significant. Data shown here are from one representative experiment performed with triplicates. 
 
. 
RAB5 has been known to have an important role in establishing a stable endo-
lysosomal system and in phagosomal maturation [108], [191]. Since, we see a strong reduction 
of Rab5 expression at gene level, the protein levels were further quantified by 
immunofluorescence using the respective antibodies in pMPs from WT and C1q-KO mice. 
Although western blots to investigate RAB5 protein expression levels would give us an 
information about the total protein levels, further investigations by immunofluorescence may 
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 RAB5+ early endosomes (green) were seen as brightly stained vesicles and located 
more towards the periphery of pMPs. Though we see a reduction in RAB5+ early endosomes 
in C1q-KO pMPs (Fig. 5.7A, lower panel) compared to WT pMPs (Fig. 5.7A, upper panel), 
manual counting of these vesicles would give us biased results. Therefore, to enumerate 
RAB5+ endosomal vesicles in an automated fashion, we employed customized macros for 
endosomal counting in ImageJ as discussed previously [196]. About 30-40 individual pMPs 
from WT and C1q-KO mice were used for quantification. As a result, it is clearly seen that the 
number of early endosomes (p < 0.001) is significantly reduced in C1q-KO pMPs (Fig. 5.7B). 
 
Figure 5.7 RAB5 expression in WT and C1q-KO mice pMPs 
A. RAB5 expression was detected by immunofluorescence in pMPs. The immunofluorescence images show RAB5 expression 
levels in pMPs of WT and C1q-KO mice. Scale for all images is 5 m. Shown here are representative images from one 
experiment out of three independent experiments. 
B. The RAB5+ vesicles were quantified by applying the automated macros to at least 30-40 cells per sample. The number of 
RAB5+ vesicles are counted and quantified and shown as MFI + SEM (n = 30 cells). Bar graphs show data from one 
representative experiment out of three with similar trend. Statistically significant difference between WT and C1q-KO mice: 
*(p < 0.05), **(p < 0.01), ***(p < 0.05).  
 
Therefore, above results demonstrate that key proteins such as RAB5, which are 
required for establishing a functional phagocytic machinery, are affected by C1q-deficiency. 
This is in line with reduced lysosomal DNASE2A expression in the C1q-KO MPs. Thus, the 
delayed uptake and digestion of apoptotic material observed in C1q-KO MPs could be due to 
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5.1.4 Does C1q-KO pMPs exhibit an acidification defect? 
Since we saw a reduction in most of the lysosomal hydrolases (Fig. 5.2, Fig. 5.3), it 
was also interesting to see if the C1q-KO pMPs have an acidification defect in the lysosomal 
compartments. To analyze this by flow cytometry, single cell suspension from peritoneum of 
WT and C1q-KO mice were analyzed with LysoTracker to stain acidic compartments (Fig. 5.8). 
We did not see any significant differences between WT and C1q-KO mice in the LysoTracker 
intensities for F4/80+CD11b+ pMPs (Fig. 5.8). This data suggests there is no substantial 





Figure 5.8 LysoTracker staining of pMPs from WT and C1q-KO mice 
WT (n = 3) and C1q-KO (n = 3) was used for quantifying LysoTracker expression in F4/80+CD11b+ pMPs using flow cytometry. 
All cells were gated on B220- CD19- population. LysoTracker MFI intensities are quantified and shown as MFI + SEM (n = 3). 
Statistically significant difference between WT and C1q-KO mice: *(p < 0.05), **(p < 0.01), ***(p < 0.05), ns – non-significant. Data 
shown here are from one representative experiment out of three. 
 
 Nevertheless, it was important to see if the acidification would occur in the lysosomal 
compartment, since the intensities obtained from flow cytometry only indicated the overall 
acidification in cells. To visualize the acidification inside of lysosomes of C1q-KO pMPs we 
used immunofluorescence microscopy. To this end, WT and C1q-KO pMPs were stained with 
anti-LAMP1 antibodies and LysoTracker to visualize the lysosomes [197] and acidification 
[198], respectively. The co-localization extent of LAMP1 and LysoTracker was quantified by 
fluorescence line scanning analysis similar to earlier studies [199], [200].  
We observed that there was a significant increase by two-fold in the size of 
LysoTracker+LAMP1+ compartments in C1q-KO pMPs (Fig. 5.9A, Fig. 5.9C). In order, to 
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scanning analysis was performed as described previously [201]. It was evident that there was 
a reduction in the co-localization efficiency of LysoTracker with lysosomes (Fig. 5.9A, Fig. 
5.9B) in C1q-KO pMPs. The co-localization efficiency correlates to the overlap of LAMP1+ and 
LysoTracker+ peaks. So, closer the overlap better is the co-localization of LysoTracker within 
LAMP1+ compartments (Fig. 5.9B).  
Taken together, this data suggests that the acidification of lysosomes is impaired in 
C1q-KO pMPs. This data provides yet another line of evidence for the disturbed endo-
lysosomal system in C1q-KO MPs. A stable endo-lysosomal system is required to create 
optimal conditions for the activity of lysosomal hydrolases such as DNASE2A to degrade 
phagocytosed apoptotic material. Thus, the failure to establish these conditions supports the 
notion of defective phagocytosis in C1q-KO mice. 
 
  
LAMP1 LysoTracker DAPI MergeA
WT
C1q-KO
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Figure 5.9 Lysosomes in WT and C1q-KO pMPs 
A. LAMP1 expression was detected by immunofluorescence microscopy in pMPs. The immunofluorescence images show 
LAMP1 expression levels in pMPs of WT and C1q-KO mice. The LysoTracker+ (red) LAMP1+ vesicles (green) were selected 
for further line scanning analysis (solid white line). One representative image of LysoTracker               co-localization with 
LAMP1+ vesicle is shown. Scale for all images is 5 m. 
B. Fluorescence line scanning analysis was performed for at least 20-23 cells per sample. Each raw data of LAMP1 (green) or 
LysoTracker (red) intensity was normalized to the highest intensity value in the region of interest (ROI). The normalized 
fluorescence intensity on the y-axis is plotted against the length (m) on the x-axis. Closer overlap between two peaks indicate 
better co-localization of LAMP1 with LysoTracker.  
C. The length of LAMP1+ vesicles is quantified and shown. Statistically significant difference between WT and C1q-KO mice: *(p 
< 0.05), **(p < 0.01), ***(p < 0.05), ****(p < 0.0001). One representative out of two independent experiments is shown here. 
5.1.4 Why is the phagocytic machinery disturbed in C1q-KO mice?  
Since we see a reduction in the early endosomes (RAB5+), an impairment in lysosomal 
acidification and enlarged lysosomal compartments in C1q-KO pMPs, we wanted to investigate 
if the known master regulator of lysosomal biogenesis Transcription factor EB (TFEB) [202] is 
affected in C1q-KO mice. Tfeb gene expression was quantified by qPCR in enriched spleen 
MPs and pMPs. It was found to be reduced approximately two-fold in C1q-KO but did not reach 
statistical significance (p = 0.08) (Fig. 5.10). 
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Figure 5.10 Gene 
expression of Tfeb in WT 
and C1q-KO mice 
mRNA from enriched spleen 
MPs (CD3-CD19-) and 
pMPs from WT and C1q-KO 
mice was used to quantify 
Tfeb gene expression            
(n = 4-5). No statistically 
significant difference was 
observed between WT and 
C1q-KO mice. Data shown 
here is from a single 




In order to further investigate TFEB expression, immunofluorescence analysis with 
TFEB-specific antibody was performed in the pMPs. We could observe a very strong reduction 
in TFEB intensity in C1q-KO pMPs (Fig. 5.11, lower panel) compared to WT (Fig. 5.11, upper 
panel). This quantification of MFI showed that TFEB protein levels were significantly reduced 
in C1q-KO pMPs (Fig. 5.11, right panel). Due to the important role of TFEB in controlling the 
lysosomal biogenesis [203], [204], it might be responsible for the phagocytosis defects 
observed in MPs of C1q-KO mice. 
 
Figure 5.11 TFEB expression in WT and C1q-KO pMPs 
TFEB expression was detected by immunofluorescence in pMPs. The immunofluorescence images show TFEB expression 
levels in pMPs of WT and C1q-KO mice. The MFI of TFEB+ vesicles is quantified and shown. Statistically significant difference 
between WT and C1q-KO mice: *(p < 0.05), **(p < 0.01), ***(p < 0.05), ****(p < 0.0001). Scale for all images is 10 m. One 
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5.2 Do phagocytosis defects trigger inflammatory pathways in C1q-KO 
mice?    
Since we found that C1q-KO MPs express diminished levels of several key proteins 
required to establish a stable phagocytic machinery, the next interesting question was to look 
for other effects from delayed degradation of phagocytosed apoptotic material in C1q-KO MPs. 
Though C1q-KO MPs take up and digest apoptotic material at a slower rate than WT MPs, it 
was interesting to test if the increased load of accumulating apoptotic material inside and 
outside of MPs act as a trigger for inflammatory cytokine production. Due to a delay in 
degradation of phagocytosed DNA, cytosolic DNA sensing pathways inside these MPs could 
be activated and lead to the production of inflammatory cytokines such as IL-1, IL-18, 
CXCL10, TNF-, IL-6 and IFN-/ [205], [206]. 
To investigate this, apoptotic HeLa cells were injected to WT and C1q-KO mice. Since 
we observed a maximum accumulation of ingested apoptotic material at 6 hours (see Fig. 5.1), 
pMPs were harvested 6-7 hours after the injection of apoptotic cells. cDNA from CD11b+ pMPs 
enriched by MACS was used to quantify gene expression of inflammatory markers. These 
results show that at steady state we do observe a slight increase in cytokine production of 
Cxcl10, Il18, Il1, and Tnf which was however, never significant in C1q-KO MPs. 
Nevertheless, when exposed to apoptotic material gene expression of inflammatory cytokines 
Il1b (p = 0.04), Il18 (p = 0.003) and Cxcl10 (p = 0.02) in C1q-KO pMPs were significantly 
upregulated in comparison to WT pMPs (Fig. 5.12). Tnf was the only inflammatory mediator 
which was not significantly altered (Fig. 5.12). Ifn-/ mRNA levels could not be detected in 
these samples by qPCR. 
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Figure 5.12 Inflammatory cytokine gene expression in the WT and C1q-KO pMPs at steady state and following in vivo 
phagocytosis.  
pMPs were enriched using anti-CD11b microbeads and subsequently were used for quantifying the mRNA expression of pro-
inflammatory cytokines. WT (n = 4) and C1q-KO mice (n = 3-4) were used for quantifying Cxcl10, Il18, Il1b and Tnfa expression 
in CD11b enriched pMPs. All bar graphs represent mean + standard error mean (SEM). Statistical significance was analyzed 
using a student’s t-test with *: p < 0.05, ** p < 0.01, *** p < 0.001. Shown here are data from one representative out of two 
independent experiments. 
 
These results support the notion that the impaired clearance of phagocytosed material 
results in a significant upregulation of inflammatory cytokines in C1q-KO pMPs. Since we found 
an increase in the mRNA levels of inflammatory cytokines, we next wanted to identify the 
signaling pathways involved. 
As we observe an accumulation of non-degraded DNA due to the DNASE2A deficiency 
in C1q-KO MPs there was potential involvement of the Stimulator of interferon genes protein 
(STING) pathway, which could be responsible for elevated inflammatory response. Once self 
or foreign DNA is sensed in the cytosol, STING recruits Tank binding kinase (TBK1) to 
endoplasmic reticulum to form STING signalosome followed by activation of Interferon 
Regulatory factor (IRF3) resulting in elevated inflammation [207].  
In order to confirm this hypothesis, apoptotic HeLa cells were injected to WT and C1q-
KO mice. After 6h cDNA from CD11b+ pMPs was used for quantifying the levels of TBK1, 
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Figure 5.13 Protein expression of TBK1, pTBK1 and STING in WT and C1q-KO mice  
TBK1, pTBK1 and STING expression was detected by Western blot in CD11b+ enriched pMPs from WT (n = 2) and C1q-KO mice 
(n = 2) at steady state and following in vivo phagocytosis conditions. The relative expression is quantified with ß-actin as 
housekeeping control. All bar graphs represent mean + standard error mean (SEM). Statistical significance was analyzed using a 
student’s t-test with *: p < 0.05, ** p < 0.01, *** p < 0.001. Shown here is one representative western blot out of two independent 
experiments. The bar graphs show pooled data from two independent experiments (n = 2). 
       
At steady-state there was a no significant difference in expression levels of TBK1, 
pTBK1 and STING in C1q-KO pMPs. However, when C1q-KO mice receive apoptotic cells we 
do see a significant increase in pTBK1 expression which is accompanied by a slight reduction 
in STING expression levels as the latter is utilized for TBK1 phosphorylation (Fig. 5.13). C1q-
KO pMPs exhibit a delayed degradation of nuclear material derived from phagocytosed 
apoptotic cells. Consequently, they show elevated levels of factors from the STING-pathway, 
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5.3 Can MFGE8-DNASE2A restore the DNA degradation?   
In an attempt to restore DNA degradation in C1q-KO MPs, we tried to target rDNASE2A 
specifically to the lysosome by attaching it to dying cells. For this, we fused DNASE2A to the 
PS-binding protein MFGE8, which has been shown to bind to apoptotic cells [91], [208]. The 
MFGE8-DNASE2A - opsonized dying cells are recognized by MPs and taken up together with 
MFGE8-DNASE2A, thereby delivering DNASE2A to the phagolysosomes. Briefly, MFGE8-
DNASE2A fusion protein was generated and further tested for its efficacy in recovering the 
phagocytosis defects observed in C1q-KO mice. 
5.3.1 Generation of MFGE8-DNASE2A fusion protein 
Mfge8-DNase2a construct was cloned into pcDNA3.1. Expression is driven by the 
Cytomegalovirus (CMV) promoter. MFGE8-DNASE2A was produced from stably transfected 
HEK 293T cells. MFGE8-DNASE2A fusion protein was purified from the supernatant by FLAG 
affinity chromatography. Expression was confirmed by Western blot. MFGE8 was detected 
around 55 kDA while MFGE8-DNASE2A fusion protein showed the expected molecular weight 
of 110 kDA (Fig. 5.14).  
 
Figure 5.14 Confirmation of MFGE8-DNASE2A by 
western blot 
The supernatant obtained from a large-scale protein 
production was loaded on to an SDS-Gel and protein of 
interest was detected with anti-MFGE8 antibodies. Lane 
1 – Supernatant (SN) from HEK cells transfected with 
MFGE8-DNASE2A; Lane 2 – Supernatant (SN) HEK 
cells only; Lane 3 – Supernatant (SN) HEK cells 
transfected with MFGE8. Arrows indicate the presence of 
respective protein. Shown here is one representative 
western blot for one MFGE8-DNASE2A fusion protein 
production out of two independent production. 
 
5.3.2 Enzymatic activity of MFGE8-DNASE2A fusion protein 
In order to test if MFGE8-DNASE2A fusion protein is enzymatically active, genomic 
DNA obtained was digested. We used equimolar concentration of rDNASE2A and rMFGE8-
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as the negative control. Indeed, MFGE8-DNASE2A was enzymatically active and degraded 
the DNA seen with a clear DNA smearing pattern however less efficiently compared to 
rDNASE2A. The undigested control shows a clear band of intact DNA (Fig. 5.15). These results 





Figure 5.15 Enzymatic activity of MFGE8-DNASE2A  
1 pg mouse tail DNA was incubated with 270µΜ or 130µΜ of rDNASE2A or 
MFGE8-DNASE2A fusion protein for 2.5h at 37°C at a pH of 5.7. Samples 
were loaded onto a 2% agarose gel. Shown here is one representative 
agarose gel for one MFGE8-DNASE2A fusion protein production out of two 
independent protein production. 
 
 
5.3.3 Functional activity of MFGE8-DNASE2A fusion protein 
To further investigate if MFGE8-DNASE2A is functionally active, apoptotic HeLa cells 
were used. Briefly, apoptotic cells were incubated with equimolar concentration of rMFGE8 
and MFGE8-DNASE2A followed by staining with anti-MFGE8 (Fig. 5.16). MFGE8-DNASE2A 
binds apoptotic cells with same efficiency as rMFGE8 as compared to uncoated cells, which 
served as a control (Fig. 5.16). These results confirm that MFGE8-DNASE2A has maintained 
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Figure 5.16 Functional activity of MFGE8-DNASE2A  
1x106 apoptotic HeLa cells were incubated with equimolar concentration of rMFGE8 or MFGE8-DNASE2A fusion protein for 30 
minutes at 4°C. Samples were then stained with anti-MFGE8 for 30 minutes at 4°C. Shown here are one representative FACS 
plots for one fusion protein production out of two independent production.  
 
5.3.4 Efficacy of MFGE8-DNASE2A to recover phagocytosis defect 
To investigate if MFGE8-DNASE2A can be used to recover the phagocytosis defect in 
C1q-KO mice an in vivo phagocytosis assay was performed. Briefly, apoptotic H2b-mCherry 
HeLa cells were coated with equimolar concentrations of either rMFGE8 or MFGE8-DNASE2A 
or left uncoated before injection into WT and C1q-KO. The peritoneal lavage was harvested 
after 7 hours and stained for CD11b and live cell markers for imaging flow cytometric analysis 
(Fig. 5.17A). 
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Figure 5.17 MFGE8-DNASE2A restores delayed degradation of nuclear material in C1q-KO mice 
A. 10x106 apoptotic mCherry HeLa cells were incubated with equimolar concentration of rMFGE8 or MFGE8-DNASE2A fusion 
protein for 30 minutes at 4°C. 10x106 apoptotic mCherry HeLa cells were injected either as uncoated, rMFGE8 coated or 
MFGE8-DNASE2A coated in separate groups to WT and C1q-KO mice. WT (n = 3) and C1q-KO (n = 3) for each group was 
injected with apoptotic mCherry HeLa cells and WT (n =1) injected with apoptotic unlabeled HeLa cells as control. pMPs from 
WT and C1q-KO mice were flushed following 7 hours of in vivo phagocytosis. Single cell suspension was stained and fixed 
for acquisition on image stream flow cytometry. 
B. The upper panel shows representative FACS plots for CD11b+mCherry+ MPs which have taken up mCherry tagged apoptotic 
cells following 7 hours of in vivo phagocytosis. Cells are gated on live cells. The lower panel shows representative FACS plots 
for mCherry+ cells (unengulfed cells) where it is gated on all cells. The FACS plots of one out of two independent experiments 
with similar outcome (n = 3-4 animals per group) are shown.  
C. The frequency as percentage of CD11b+ mCherry+ (left panel) and mCherry+ (right panel) is quantified and shown. Statistically 
significant differences between WT and C1q-KO mice: **(p < 0.01), ***(p < 0.05).  
 
The frequency of CD11b+mCherry+ cells was significantly increased at least by four-
fold in C1q-KO mice compared to WT following 7 hours of in vivo phagocytosis (p = 0.001). 
When C1q-KO mice received MFGE8-coated apoptotic cells, the frequency of 
CD11b+mCherry+ cells were decreased by 2-fold. Importantly, however, when C1q-KO mice 
received MFGE8-DNASE2A coated apoptotic cells there was a further reduction of 
unlabelled ap.cells
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CD11b+mCherry+ cells to WT levels in comparison to C1q-KO mice injected with uncoated 
apoptotic cells (p = 0.004) (Fig. 5.17B, upper panel and Fig. 5.17C, left panel). 
The unengulfed cells represent the injected apoptotic H2b-mCherry HeLa cells which 
are not taken by the MPs and gated as CD11b-mcherryhigh. The frequency of unengulfed cells 
in C1q-KO mice which received uncoated apoptotic cells shows a significant increase by four-
fold. However, we saw an almost two-fold reduction in the frequency of unengulfed cells in 
C1q-KO mice injected with MFGE8-coated apoptotic cells. In addition, we also observed a 
more striking significant reduction in the frequency of unengulfed cells in C1q-KO mice which 
received MFGE8-DNASE2A coated apoptotic cells (p = 0.003) (Fig. 5.17B, lower panel and 
Fig. 5.17C, right panel).  
Thus, from these observations it is evident that administration of MFGE8-DNASE2A 
coated apoptotic cells seems to increase the rate of phagocytosis and also promotes the 
apoptotic DNA degradation in C1q-KO mice. This strategy is more efficient in comparison to 
administration of MFGE8 coated apoptotic cells. Due to the higher efficiency of MFGE8-
DNASE2A over MFGE8 in rectifying the delayed uptake and degradation of apoptotic cells we 
next investigated if this had an impact on the inflammation in C1q-KO mice. 
5.3.5 Efficacy of MFGE8-DNASE2A to reduce inflammation in C1q-KO mice  
Since the administration of MFGE8-DNASE2A coated apoptotic cells helped to restore 
the delayed uptake and degradation of apoptotic material in C1q-KO mice, we expected an 
impact on the onset of inflammatory signals. 
In order to address if MFGE8-DNASE2A has the capability to reduce the inflammatory 
responses induced by an elevated accumulation of phagocytosed material inside C1q-KO 
MPs, uncoated apoptotic cells, or apoptotic cells coated with equimolar concentration of 
rMFGE8 or MFGE8-DNASE2A were injected into WT and C1q-KO mice. The peritoneal lavage 
was then harvested and analyzed for inflammatory parameters both at gene and protein level 
(Fig. 5.18A).  
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Figure 5.18 Inflammation induced by impaired degradation is reduced by MFGE8-DNASE2A in C1q-KO mice:  
A. 10x106 apoptotic HeLa cells were incubated with equimolar concentration of rMFGE8 or MFGE8-DNASE2A fusion protein 
for 30 minutes at 4°C. 10x106 apoptotic mcherry HeLa cells were injected either as uncoated or MFGE8-coated or MFGE8-
DNASE2A-coated in separate groups to WT and C1q-KO mice. WT (n = 3-4) and C1q-KO (n = 3-4) for each group were 
injected with apoptotic mCherry HeLa cells. pMPs from WT and C1q-KO mice were flushed following 7 hours of in vivo 
phagocytosis and enriched for CD11b+ pMPs by MACS. 
B. 1 µg of RNA from the enriched CD11b+ pMPs was reverse transcribed and used for quantifying mRNA levels of IL18 and 
IL1b. Shown data are relative expression quantified with GAPDH as housekeeping control. All bar graphs represent mean 
+ standard error mean (SEM). Statistical significance was analyzed using a student’s t-test with *: p < 0.05, ** p < 0.01, 
*** p < 0.001. Shown here are data from one representative experiment out of two. 
C. Western blot showing TBK1 and pTBK1 levels in pMPs of WT (n = 2) and C1q-KO (n = 2) at steady state and following in 
vivo phagocytosis with each treatment. The relative expression is quantified with b-tubulin as housekeeping control. 
Shown western blot is a one representative out of three experiments and data for bar graphs is pooled from two 
independent experiments. 
 
cDNA from CD11b+ pMPs was used for quantification of inflammatory markers at 
mRNA level. C1q-KO mice that received uncoated apoptotic cells, showed a significant 
increase in gene expression of Il18 (p = 0.006) compared to WT mice. However, C1q-KO mice 
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expression of Il18 as compared to these mice administered with uncoated apoptotic cells. 
Nevertheless, upon administration of MFGE8-DNASE2A coated apoptotic cells there is a 
significant reduction in the Il18 expression between C1q-KO mice exposed to either uncoated 
(p = 0.0094) or rMFGE8 coated apoptotic cells (p = 0.0014) at gene level (Fig. 5.18B, left 
panel). Next, C1q-KO mice exposed to uncoated apoptotic cells, showed a significant increase 
in gene expression of IL1b (p = 0.0077) compared to WT mice. In addition, administration of 
rMFGE8 coated apoptotic cells to C1q-KO mice significantly reduced the gene expression of 
Il1b compared to these mice that received uncoated apoptotic cells (p = 0.0034). However, 
administration of MFGE8-DNASE2A coated apoptotic cells to C1q-KO mice resulted in 
significant reduction in IL1b expression compared to either uncoated (p = 0.0019) or rMFGE8 
coated apoptotic cells (p = 0.0073) at gene level (Fig. 5.18B, right panel).  
These results support the idea that MFGE8-DNASE2A is successful in eliminating the 
excess accumulation of phagocytosed apoptotic material inside the MPs thereby reducing 
inflammatory cytokine production in C1q-KO mice. Since these inflammatory cytokines are 
induced via STING pathway it was also important to see if MFGE8-DNASE2A treatment had 
an impact on STING pathway. Protein lysates from CD11b+ pMPs enriched by MACS were 
used for quantifying the levels of TBK1 and pTBK1 to in order to identify the activation status 
of STING pathway. Western blots showed that administration of uncoated apoptotic cells to 
C1q-KO MPs resulted in increased TBK1 phosphorylation, corroborating our previous findings 
(Fig. 5.13, middle panel). However, when rMFGE8 coated apoptotic cells were administered, 
TBK1 phosphorylation was reduced (Fig. 5.18C). Application of the fusion protein MFGE8-
DNASE2A to apoptotic cells could reduce TBK1-phosphorylation even further (Fig. 5.18C), a 
phenomenon, which was observed not only in C1q-KO, but also in WT pMPs (Fig. 5.18C). A 
low molecular weight faint protein band observed on western blot in some of the protein 
samples might be due to unknown post-translational modifications. These results confirm that 
MFGE8-DNASE2A has a positive impact on promoting phagocytosis and degradation of 
nuclear material thereby reducing the inflammation via STING pathway in (Fig. 5.18C). 
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6 DISCUSSION 
The clearance of apoptotic cells by phagocytosis plays an important role in 
protecting tissues from exposure to inflammatory and harmful contents of dying cells. 
There are a number of complementary receptor-ligand systems identified to facilitate 
phagocytosis [209]. Though the role of the complement system has been shown by 
many studies in phagocytosis of apoptotic cells the precise cellular mechanism of how 
C1q deficiency results in SLE development is unclear. The reports available so far 
indicate C1q can have a dual role, both protective and a detrimental in SLE 
pathogenesis. This study was aimed to investigate the possible mechanisms of how 
C1q deficiency contributes towards lupus pathogenesis using a homozygous knockout 
of C1q on a mixed background. We observed a delayed degradation of nuclear 
material derived from apoptotic cells in C1q-KO mice. This is due to the DNASE2A 
deficiency in C1q-KO MPs. Due to this longer retention of nuclear material inside the 
cytosol, STING pathway is triggered which is responsible for inducing inflammatory 
phenotype in C1q-KO mice. We also observed disturbances in endo-lysosomal system 
of C1q-KO MPs. Nevertheless, it is still unclear why C1q-KO mice exhibit these 
lysosomal defects. 
 
6.1 C1q-KO mice exhibit a phagocytosis defect 
C1q has been shown to bind directly to the surface blebs of apoptotic cells in 
vitro [163], [210], [211], indicating that it promotes their clearance thereby preventing 
further activation of immune system by autoantigens. In order to investigate the 
influence of C1q on phagocytosis an in vivo phagocytosis assay was performed. We 
have shown that C1q-KO MPs phagocytose apoptotic material slower than control 
mice in vivo. In addition, an unexpected finding was a significant increase in the 
frequency of MPs with non-degraded apoptotic nuclear material in C1q-KO mice (Fig. 
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5.1). The uptake defect in C1q-KO mice observed in our study is in agreement with a 
previous study wherein it was shown that homozygous C1q deficiency on a mixed 
background mouse develop glomerulonephritis by a C3-independent pathway. These 
mice had significantly higher amounts of autoantibodies and uncleared apoptotic cells 
in the kidneys which implicate a phagocytosis defect [169]. In addition, a similar uptake 
defect was also observed in lupus prone MRL/Mp or NZB/W resident pMPs both in 
vivo and in vitro [212]. However, up to now an impaired degradation of phagocytosed 
material in C1q-KO mice and other lupus prone mice has never been reported. 
Nevertheless, MFGE8-deficient mice on a C57Bl/6x129 genetic background 
developed lupus due to defective uptake as well as an altered intracellular processing 
which results in enhanced self-antigen presentation [213]. It has been shown that an 
appropriate time point is important while investigating the differences in apoptotic cell 
uptake by MPs [186]. Unlike the previous studies in our experiments we analysed the 
apoptotic cell uptake following 3 hours to 16 hours in vivo which gave us information 
regarding not only the uptake, but also the degradation of engulfed apoptotic cells. So 
far it was hypothesized that during C1q deficiency unengulfed apoptotic cells act as a 
trigger for interferon (IFN) production. Therefore, we followed to study the 
consequences for the longer retention of nuclear material inside C1q-KO MPs. 
 
6.2 Inflammation is a consequence of phagocytosis defect in C1q-KO 
mice 
Our proteome analysis revealed that C1q-KO splenic enriched MPs exhibit 
reduced expression of lysosomal hydrolases and other proteases. We observed that 
DNASE2A, an important lysosomal hydrolase was significantly downregulated in C1q-
deficient splenic enriched MPs both at gene and protein level. DNASE2A has been 
previously shown to degrade the nuclei expelled from the erythroid precursors or DNA 
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following the engulfment of apoptotic cells by MPs [214]. In addition, it was also shown 
that many MPs containing undigested DNA accumulates in the fetal liver of DNASE2A 
deficient embryos [215],[216]. From earlier studies it was evident that DNASE2A-/- 
embryos die in utero late in embryogenesis due to high levels of type-1 IFN [189]. In 
addition, conditional ablation of DNASE2A and IFNAR in mice leads to the production 
of inflammatory cytokines such as IL6, TNF, CXCL10, IL1 and other type-1 IFNs. 
These mice eventually succumb to autoimmune disease associated with polyarthritis 
[217]. Therefore, we speculated that a delay in degradation of nuclear material 
observed in C1q-KO mice might be due to DNASE2A deficiency.  
We could show that following an in vivo phagocytosis, C1q-KO mice show 
elevated pro-inflammatory cytokine levels such as IL1, CXCL10, IL18 and TNF (Fig. 
5.12) which is in concordance with these previous studies. The secretion of pro-
inflammatory cytokines such as IFN, IL1, IL18, TNF has been shown to promote 
tissue damage in SLE patients [218]–[221]. As a consequence, circulating immune 
complex deposits in organs and joints resulting in complement system activation which 
in turn attracts many innate immune cells thereby promoting local inflammation. In 
addition, pDCs are activated by immune complex deposits which also favours IFN- 
secretion. As a result of a persistent inflammatory milieu, irreversible organ damage 
occurs thereby turning into a vicious cycle by increasing the load of apoptotic cells [80], 
[222]. Unfortunately, in our experiments IFN or IFN levels by qPCR could not be 
detected and further investigations using a high sensitivity ELISA is required to confirm 
these results.  
Furthermore, the STING pathway was activated causing elevated expression of 
TBK1 and pTBK1 in C1q-KO mice during an in vivo phagocytosis assay. This implies 
that non-degraded DNA inside the MPs is sensed by cGAS which further activates the 
STING pathway and results in an inflammatory phenotype in C1q-KO mice. This is in 
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line with a previous finding which demonstrates the role of STING by transplanting 
DNASE2A deficient bone marrow to WT mice. Following transplantation, these mice 
developed inflammatory arthritis similar to systemic-onset juvenile idiopathic arthritis 
[190]. However, the ablation of STING resulted in reversal of the inflammatory 
phenotype and improved the survival rate which further indicates the importance of 
STING [205]. 
Apart from STING there are other cytosolic sensing mechanisms through which 
inflammation is induced such as absent in melanoma (AIM2). AIM2 acts independent 
of the STING pathway. This was shown with the triple deficient DNASE2A-/-/IFNAR-/-
/STING-/- mice which exhibit autoantibody production [223]. At this point, it was evident 
that DNASE2A also regulates inflammation and autoimmunity through other 
mechanisms. However, deletion of UNC93B1, a major adaptor for TLR7 and TLR9, on 
a DNase2a-/-IFNAR-/- background blocked autoantibody production but fails to confer 
protection from arthritis [224]. In addition, DNase2a-/-AIM2-/- mice were lethal 
supporting the notion that AIM2 is not a pathway responsible for triggering inflammation 
in DNASE2A deficient mice [223]. Thus, from above studies it is evident that DNASE2A 
plays multiple critical roles in regulating or preventing DNA-driven inflammation.  
Taken together, due to DNASE2A deficiency in C1q-KO MPs the nuclear 
material is retained longer in its cytosol. Furthermore, this longer retention of DNA 
triggers the cytosolic sensing pathways via cGAS-STING axis and results in an 
inflammatory phenotype in C1q-KO. Moreover, autoantibodies detected in SLE 
patients are mostly against DNA and nuclear material. Our results so far may indicate 
that the undegraded material may escape cells as self-antigens and thereby trigger 
autoantibody production.  
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6.3 C1q-KO mice exhibit a dysfunctional phagocytic machinery 
Our proteome analysis also revealed that C1q-KO pMPs exhibit a significant 
reduction in important RAB-GTPases such as RAB5, RAB9 AND RAB11FIP1. RAB5 
has been demonstrated to regulate tethering and fusion of early endosomes thereby 
playing a critical role in phagosome maturation. RAB5 is also required for the 
recruitment of RAB7 which regulates the phagosome fusion with late endosomes to 
facilitate the elimination of apoptotic cells [101], [194]. More recently it was shown that 
reduction of RAB5 in hepatocytes results in loss of the endo-lysosomal pathway by 
almost 80% accompanied by a reduction in lysosomes and recycling endosomes [191]. 
Consistent with this notion, our results indicate that the RAB5 reduction in C1q-KO 
MPs destabilizes the endo-lysosomal pathway required for effective degradation of 
phagocytosed apoptotic material. This further correlates with an accumulation of 
enlarged lysosomes as seen in C1q-KO MPs which is essential for efficient 
degradation of ingested apoptotic cells. LAMP1 and LAMP2 dysfunctional MPs exhibit 
an arrested phagosomal maturation although these MPs phagocytosed particles 
normally [225]. In addition, these lysosomes have an impaired ability to move towards 
the microtubule organizing centre which further hinders the interaction with other 
phagosomal compartments [225]. Our results strongly suggest that C1q-KO MPs fail 
to establish a functional phagocytic machinery causing reduced lysosomal DNASE2A 
levels. 
Furthermore, our proteomic screen showed a reduction in V-ATPases such as 
ATP6v1f and ATP6v1b2 in C1q-KO splenic MPs. Vacuolar H+-ATPase (v-ATPase) is 
a multimeric proton pump involved in pH homeostasis, membrane trafficking and 
protein degradation [226]. It is required for the acidification of lysosomes, late 
endosomes, autophagic and phagocytic vesicles [227], [228]. Therefore, it is likely that 
C1q-KO MPs have an acidification defect due to a reduction in important V-ATPases. 
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However, from LysoTracker staining of pMPs no substantial differences between WT 
and C1q-KO mice in the LysoTracker intensities were seen (Fig. 5.8). This might 
indicate that acidic compartments are functional in C1q-KO mice. Nevertheless, when 
investigated by immunofluorescence, surprisingly, we could observe a reduced co-
localization of LysoTracker with the lysosomal compartments in C1q-KO MPs (Fig. 
5.9). This suggests that acidification inside the lysosomes could be impaired in C1q-
KO mice. It has been shown from previous studies that proper lysosomal acidification 
is required for optimal degradative activity of lysosomal hydrolases [229]. Furthermore, 
it has been reported that impaired lysosomal acidification contributes to lysosomal 
storage disorders (LSDs) such as Batten disease [230]–[232]. In addition, defective 
lysosomal acidification regulation has been reported in Alzheimer and Parkinson 
diseases [233]–[235]. The reduction of lysosomal acidification in MPs could be also an 
underlying reason for DNASE2A reduction in C1q-KO MP since it is shown that 
DNASE2A functional activity requires an optimal acidic pH inside the lysosomal 
compartment [236].    
6.4 Diminished TFEB expression in C1q-KO MPs 
The biogenesis and further functioning of endosomal-lysosomal pathway is 
controlled by the transcription factor EB (TFEB) which regulates almost 471 genes that 
constitute the CLEAR gene network (coordinated lysosomal expression and 
regulation). The CLEAR network includes numerous lysosomal hydrolases, membrane 
proteins and acidification proteins [204], [237]. It has also been shown that TFEB 
overexpression results in an elevated number of lysosomes and higher levels of 
lysosomal enzymes thereby subsequently increases the lysosomal catabolic activity 
[202].  
To this end, TFEB expression was quantified by immunofluorescence and we 
could observe that the TFEB expression was reduced in C1q-KO pMPs at steady state. 
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Therefore, the diminished expression of TFEB could be a reason for the impaired 
lysosomal biogenesis seen in C1q-KO mice. From earlier studies, it was shown that 
TFEB overexpression favours MHC-II dependent antigen presentation by enhancing 
lysosome hydrolytic activity and preserving exogeneous antigens [238]. Moreover, 
recently it was identified that Fc receptor activation during phagocytosis promotes 
TFEB translocation to nucleus. In addition, upregulation in TFEB expression occurs 
during phagosomal maturation with the help of lysosomal Ca2+ release [239]. Indeed, 
it was also shown that TFEB overexpression helps to resolve some defects in 
lysosomal storage disorders [240], [241]. 
In summary, C1q-KO mice exhibit multiple defects in the endo-lysosomal 
machinery. Defects in lysosomal acidification together with the inability to establish a 
stable phagocytic machinery in C1q-KO pMPs could be a plausible explanation for the 
reduced DNASE2A levels. Moreover, C1q-KO pMPs also show reduced TFEB 
expression which is a major transcription factor for lysosomal biogenesis.  
6.5 MFGE8-DNASE2A administration does have a therapeutic potential 
Our data suggest that MFGE8-DNASE2A fusion protein is efficient not only to 
restore DNA degradation but also to improve uptake of apoptotic cells in C1q-KO mice. 
MFGE8 was previously implicated in regulating phagocytosis through its interaction 
with Crk-DOCK180-Rac1 pathway. Rac1 aggregates at the cell membrane which 
further promotes the formation of protrusion thereby facilitating phagocytosis [242]. 
The inflammatory phenotype observed in C1q-KO following in vivo phagocytosis was 
resolved when MFGE8-DNASE2A coated apoptotic cells were administered. In 
addition, administration of MFGE8-DNASE2A coated apoptotic cells were more 
efficient compared apoptotic cells coated with rMFGE8 only in resolving phagocytosis 
defects as well as inflammation (Fig 5.18). In the context of previously reported 
findings, we noticed that rMFGE8 promotes phagocytosis and partially compensates 
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for the uptake defect observed in C1q-KO mice. MFGE8 has been known to inhibit the 
release of pro-inflammatory cytokines such as IL-1β, TNF-α and IL-6 by suppressing 
MAPK, NF-κB, ERK1/2 activation, thus plays an important role in anti-inflammation 
[243]–[245]. However, surprisingly we saw that there was no reduction in the IL18 
levels in C1q-KO mice when they were administered rMFGE8 coated apoptotic cells. 
We speculate at this point that rMFGE8 promotes phagocytosis and given the inability 
of C1q-KO MPs to degrade DNA the high load of cytosolic DNA might favour IL18 
production. Taken together, the fusion of MFGE8 to DNASE2A provides a tool for 
increasing the amount of DNASE2A inside the C1q-KO MPs thereby providing a 
promising tool for the treatment of autoimmune disorders associated with aberrant 
recognition of self-DNA. 
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7 GRAPHICAL ABSTRACT 
 
Figure 7.1 Model for generation of autoimmunity in C1q-KO mice 
 
WT MPs (left) take up apoptotic cells (orange) and degrade them inside the lysosomal compartments. WT MPs exhibit 
normal endo-lysosomal system with sufficient DNASE2A expression inside the lysosomes. The residual DNA inside the 
lysosomes is sufficient to activate STING pathway and results in normal inflammatory responses. 
 
C1q-KO MPs (right) take up apoptotic cells (orange) and degrade slowly compared to WT. C1q-KO MPs disturbed endo-
lysosomal system with insufficient DNASE2A expression inside the lysosomes. The load of residual DNA inside the 
lysosomes is more compared to WT MPs. This increased residual DNA leads to aberrant activation of STING pathway 
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8 OUTLOOK 
 
SLE is a complex disease with great heterogeneity in symptoms. Novel 
immunotherapies under development include targeting co-stimulatory molecules, cytokines or 
its respective receptors, cell based and peptide therapies. However, there is a need to 
explore the wide array of immunotherapies due to its high failure rate in clinical trials. Our in 
vivo results from mouse models are promising and it is important to investigate DNASE2A 
expression in lupus patients. To achieve this, in future studies monocytes from lupus patients 
will be used to quantify DNase2a on RNA and protein level, respectively. Our strategy to 
restore DNASE2A function in MPs by fusing DNASE2A to the apoptotic-cell binding protein 
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9 APPENDIX 
9.1 Spleen enriched MPs proteomics 
 Downregulated (1.2 fold) 
Gene Name Protein Name 
Cmbl Carboxymethylenebutenolidase homolog 
Akr1b7 Aldo-Keto Reductase Family 1 Member B7 
Vcam1 Vascular cell adhesion protein 1 
Gpd1 Glycerol-3-Phosphate Dehydrogenase 1 
Crip2 Cysteine-rich protein 2 
Emr1 Adhesion G protein-coupled receptor E1 
Asah1 Acid ceramidase 
Itga9 Integrin  - 9 
DNase2a Deoxyribonuclease-2-alpha 
C3 Complement C3 
CtsB Cathepsin B 
CtsD Cathepsin D 
Man2b2 Epididymis-specific alpha-mannosidase 
Bloc1s1 Biogenesis of Lysosomal Organelles Complex 1 Subunit 1 
LAMP2 Lysosomal-associated membrane protein 2 
Lipa Lysosomal acid lipase 
ATP6v1b2 ATPase H+ Transporting V1 Subunit B2 
ATP6v1f ATPase H+ Transporting V1 Subunit F 
 
 
 Upregulated (1.2 fold) 
Gene Name Protein Name 
PepD Peptidase D 
Aurka Aurora Kinase A 
Abt1 Activator Of basal Transcription 1 
Pacsin1 Protein Kinase C And Casein Kinase Substrate In Neurons 1 
CtsA Cathepsin A 
Lamp1 Lysosomal - associated membrane protein 1 
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9.2 pMPs proteomics 
 Downregulated candidates (3 - fold) 
Gene Name Protein Name 
C1qa Complement subunit A 
Ctse Cathepsin A 
Dr1 Protein Dr1 
Fscn1 Ficolin-1 
Hgsnat Heparan-alpha-glucosaminide N-acetyltransferase 
Vamp7 Vesicle-associated membrane protein 7 
Vamp8 Vesicle-associated membrane protein 8 
Lamp1 Lysosomal-associated membrane protein 1 
Lamp2 Lysosomal-associated membrane protein 2 
Lipa Lysosomal acid lipase 
Man2b2 Mannosidase Alpha Class 2B Member 2 
Rab5b Ras-related protein Rab-5B 
Rab9a Ras-related protein Rab-9a 
Rab11b Ras-related protein Rab-11b 
Rassf2 Ras Association Domain Family Member 2 
Rab11fip1 RAB11 Family Interacting Protein 1 
Rpl28 60S ribosomal protein L34 
Rpl34 60S ribosomal protein L34 
S100a11 S100 Calcium Binding Protein A11 
Syne1 Spectrin Repeat Containing Nuclear Envelope 
Protein 1 
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 Upregulated candidates (3 - fold) 
Gene Name Protein Name 
Fcgr2 Low affinity immunoglobulin gamma Fc region receptor II 
 
Serpinb10 Serpin peptidase inhibitor, clade B (ovalbumin), member 10 
Retnla Resistin-like alpha 
CtsE Cathepsin E 
Chil4 Chitinase-like protein 4 
Gna01 Guanine nucleotide-binding protein G(o) subunit alpha 
Arg1 Arginase-1 
Slc7a2 Cationic amino acid transporter 2 
Chil3 Chitinase-like protein 3 
Slc11a1 Natural resistance-associated macrophage protein 1 
Golga3 Golgin subfamily A member 3 
Grk6 G protein-coupled receptor kinase 6 
Ppp6c Serine/threonine-protein phosphatase 6 catalytic subunit 
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9.3 Primer sequences 
Gene FP (5’ – 3’) RP (5’ – 3’) 
Annealing 
Temperature 
DNase2a TGGAAGGCTTCTTCGCTCAG CTGGACCTGTAGGTTGGTGC 56 
Rab5 CCAACGGGCCAAATACTGGA ACCGTTCTTGACCAGCTGTA 56 
Rab9 GGACAACGGCGACTATCCTT GAGTTTGGCTTGGGCTTTCG 56 
Lamp1 CCTACGAGACTGCGAATGGT CCACAAGAACTGCCATTTTTC 56 
Tfeb GCATCAGAAGGTTCGGGAGT CGGGGTTGGAGCTGATATGT 56 
Cxcl10 GCCGTCATTTTCTGCCTCATC TAGGCTCGCAGGGATGATTTC 56 
Il18 GGCTGCCATGTCAGAAGACTC GTGAAGTCGGCCAAAGTTGT 56 
Il1 CAGGCAGGCAGTATCACTCA AGCTCATATGGGTCCGACAG 56 
Tnf GAACTGGCAGAAGAGGCACT AGGGTCTGGGCCATAGAACT 56 
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